var title_f32_2_32800="Welders keratitis";
var content_f32_2_32800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flash burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows fluorescein uptake in diffuse punctate lesions of the cornea caused by ultraviolet radiation, in this case from an electric welding arc. Sunlight can also cause such an injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32800=[""].join("\n");
var outline_f32_2_32800=null;
var title_f32_2_32801="MRI right occipital infarct";
var content_f32_2_32801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right occipital infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial FLAIR MRI images showing a right occipital infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32801=[""].join("\n");
var outline_f32_2_32801=null;
var title_f32_2_32802="Mitosis in thymic carcinoid";
var content_f32_2_32802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well-differentiated thymic carcinoid: histology showing a mitotic figure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carcinoid tumors in the thymus often display areas of necrosis and mitotic figures (arrow). (Hematoxylin and eosin, magnification 250x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32802=[""].join("\n");
var outline_f32_2_32802=null;
var title_f32_2_32803="Patient information: What can go wrong after a heart attack? (The Basics)";
var content_f32_2_32803=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16434\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/42/9888\">",
"         Normal heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/43/16050\">",
"          Pitting edema",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/6/37987\">",
"         Patient information: Heart attack recovery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/27/21940\">",
"         Patient information: Medicines after a heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/60/19394\">",
"         Patient information: Mitral regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/12/25795\">",
"         Patient information: Ventricular fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/59/27575\">",
"         Patient information: Mitral regurgitation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: What can go wrong after a heart attack? (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/what-can-go-wrong-after-a-heart-attack-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25937959\">",
"      <span class=\"h1\">",
"       Why can problems happen after a heart attack?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Problems can happen because part of the heart is damaged or dies during a heart attack. This can cause the heart to beat abnormally. The damage can also lead to problems with the heart walls or valves (",
"      <a class=\"graphic graphic_figure graphicRef56936 \" href=\"mobipreview.htm?9/42/9888\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Whether or not problems happen after a heart attack and how serious they are depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How serious the heart attack was, how much of the heart was damaged, and which part of the heart was damaged",
"       </li>",
"       <li>",
"        How quickly the heart attack was treated",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25937966\">",
"      <span class=\"h1\">",
"       What problems can happen after a heart attack?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen in the days to weeks after a heart attack. Some problems are not too serious and can be treated, but others can cause death.",
"     </p>",
"     <p>",
"      The most common problems that can happen after a heart attack are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Abnormal heart rhythms",
"        </strong>",
"        &mdash; Each person has a built-in electrical system in the heart that controls his or her heartbeat. After a heart attack, the electrical signals that control the heartbeat can become abnormal and cause an abnormal heart rhythm. Abnormal heart rhythms are also called &ldquo;arrhythmias.&rdquo;",
"        <br/>",
"        <br/>",
"        An abnormal heart rhythm can cause people to feel like their heart is racing, skipping beats, or beating out of sync. An abnormal heart rhythm can also cause dizziness, fainting, or even death.",
"        <br/>",
"        <br/>",
"        Treatment depends on the type of abnormal rhythm and the person&rsquo;s symptoms and can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        &ldquo;Watching and waiting&rdquo; &mdash; If your abnormal heart rhythm isn&rsquo;t too serious, the doctor might watch it to see if it goes away on its own.",
"       </li>",
"       <li>",
"        Different types of medicines",
"       </li>",
"       <li>",
"        A procedure called &ldquo;cardioversion,&rdquo; which involves applying a mild electrical current to the heart to fix its rhythm",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        &mdash; Heart failure is a condition in which the heart does not pump as well as it should. This can cause symptoms such as swelling (",
"        <a class=\"graphic graphic_picture graphicRef61706 \" href=\"mobipreview.htm?15/43/16050\">",
"         picture 1",
"        </a>",
"        ), trouble breathing, and feeling tired. Sometimes, heart failure after a heart attack lasts only for a short time. Other times, heart failure after a heart attack becomes a long-term problem.",
"        <br/>",
"        <br/>",
"        Doctors can treat heart failure with different types of medicines. (See",
"        <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"         \"Patient information: Medicines for heart failure (The Basics)\"",
"        </a>",
"        .) The medicines can improve symptoms and help people feel better. Some medicines help people live longer. Most people need to take more than 1 medicine every day.",
"       </li>",
"       <li>",
"        <strong>",
"         Inflammation of the lining around the heart",
"        </strong>",
"        &mdash; When the lining around the heart gets inflamed or irritated, doctors call it &ldquo;pericarditis.&rdquo; Pericarditis can cause chest pain that gets worse when you cough or take a deep breath. Sometimes, it also causes a fever.",
"        <br/>",
"        <br/>",
"        If you have pericarditis, your doctor will probably first treat it by increasing your daily dose of",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        . (After a heart attack, most people take aspirin every day.) He or she might also prescribe another NSAID. NSAIDs are a large group of medicines that includes aspirin,",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/34/550?source=see_link\">",
"         indomethacin",
"        </a>",
"        (sample brand names: Indocin&reg;, Indocid&reg;), and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"        <br/>",
"        <br/>",
"        If the inflammation causes fluid to collect around your heart, your doctor might drain the fluid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other problems can happen after a heart attack, but they are much less common. These problems usually happen within the first few days after a heart attack and can be life-threatening. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tears in the heart muscle or heart walls",
"       </li>",
"       <li>",
"        Problems with the heart valves",
"       </li>",
"       <li>",
"        Blood clots in the lung",
"       </li>",
"       <li>",
"        Strokes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These problems usually cause sudden and severe symptoms, such as sudden trouble breathing or passing out. They need emergency treatment, which might include medicines, surgery, or other procedures. But these problems can&rsquo;t always be treated and sometimes lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25937973\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=see_link\">",
"       Patient information: Heart attack recovery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"       Patient information: Medicines after a heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/60/19394?source=see_link\">",
"       Patient information: Mitral regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/12/25795?source=see_link\">",
"       Patient information: Ventricular fibrillation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=see_link\">",
"       Patient information: Mitral regurgitation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/2/32803?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16434 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32803=[""].join("\n");
var outline_f32_2_32803=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25937959\">",
"      Why can problems happen after a heart attack?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25937966\">",
"      What problems can happen after a heart attack?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25937973\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/42/9888\">",
"      Normal heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/43/16050\">",
"       Pitting edema",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=related_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/12/25795?source=related_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_2_32804="Transient tachypnea of the newborn";
var content_f32_2_32804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transient tachypnea of the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Karen E Johnson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32804/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/2/32804/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient tachypnea of the newborn (TTN) is a parenchymal lung disorder characterized by pulmonary edema resulting from delayed resorption and clearance of fetal alveolar fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/1\">",
"     1",
"    </a>",
"    ]. TTN is a common cause of respiratory distress in the immediate newborn period. In a review of 33,289 term deliveries (37 to 42 weeks), the incidence of TTN was 5.7 per 1000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/2\">",
"     2",
"    </a>",
"    ]. Although thought to be a benign, self-limited condition, there are increasing data to suggest that TTN increases a newborn's risk for developing a wheezing syndrome early in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of clearing fetal alveolar fluid begins before term birth and continues through labor and after delivery. During late gestation, in response to increased concentrations of catecholamines and other hormones, the mature lung epithelium switches from actively secreting chloride and liquid into the air spaces to actively reabsorbing sodium and liquid (",
"    <a class=\"graphic graphic_figure graphicRef57746 \" href=\"mobipreview.htm?17/45/18132\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Increased oxygen tension at birth enhances the capacity of the epithelium to transport sodium and increases gene expression of the epithelial sodium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/5\">",
"     5",
"    </a>",
"    ]. Reduced gene expression of this channel contributes to the inability of immature lungs to switch from fluid secretion to absorption and can be upregulated by glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Passive resorption of liquid also occurs after birth because of differences among the oncotic pressure of air spaces, interstitium, and blood vessels. The majority of water transport across the apical membrane is thought to occur through aquaporin 5 (AQP5) water channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed resorption of fetal lung fluid is thought to be the underlying cause of TTN. Fluid fills the air spaces and moves into the interstitium, where it pools in perivascular tissues and interlobar fissures until it is eventually cleared by the lymphatics or absorbed into small blood vessels. The excess lung water in TTN results in decreased pulmonary compliance. Tachypnea develops to compensate for the increased work of breathing associated with reduced compliance. In addition, accumulation of fluid in the peribronchiolar lymphatics and interstitium promotes partial collapse of the bronchioles with subsequent air trapping. Continued perfusion of poorly ventilated alveoli leads to hypoxemia, and alveolar edema reduces ventilation, sometimes resulting in hypercapnia.",
"   </p>",
"   <p>",
"    In one study, the expression of AQP5 was greater in patients with TTN than those with respiratory distress syndrome or controls. This finding suggests that upregulation of AQP5 increases reabsorption of postnatal lung fluid, which contributes to the quick resolution of symptoms in infants with TTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased surfactant function has also been proposed as contributing to the pathophysiology of TTN. In one small study of term infants delivered via elective cesarean delivery, patients with TTN compared with age-matched controls were more likely to have lower surfactant function as determined by gastric aspirate measurement of lamellar body count and stable microbubble test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/7\">",
"     7",
"    </a>",
"    ]. However, further studies are needed to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTN develops in infants born prematurely or after cesarean delivery without labor because mechanisms to reabsorb alveolar fluid have not been initiated as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 29,669 deliveries from 1992 to 1999 from a single center in the United States, TTN occurred in more infants after elective cesarean than after vaginal delivery (3.1 versus 1.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a German study that analyzed data from perinatal regional registries of almost 240,000 term deliveries from 2001 to 2005, the incidence of TTN was 5.9 cases per 1000 singleton births [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/9\">",
"       9",
"      </a>",
"      ]. Elective cesarean section was the most significant risk factor associated with TTN compared to data from the national German perinatal registry (42 percent versus 9 percent). Other risk factors associated with TTN included small for gestational age (16 versus 10 percent), large for gestational age (14 versus 11 percent), and male gender (60 versus 51 percent).",
"     </li>",
"     <li>",
"      In a multicenter Norwegian study, there was a two-fold higher risk for pulmonary disorders (ie, TTN and neonatal respiratory distress syndrome) for infants born after planned cesarean delivery compared to those born after planned vaginal delivery (1.6 versus 0.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TTN occurs two to three times more commonly in infants of diabetic mothers (IDM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .) The mechanism may be related to decrease fluid clearance in the diabetic fetal lung, although cesarean delivery, which is more frequently performed in pregnancies of diabetic mother, is a contributing factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal asthma is a risk factor, although the mechanism is unknown. In one study, infants of asthmatic mothers were more likely to have TTN than were controls (OR 1.8, 95% CI 1.4-2.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/13\">",
"     13",
"    </a>",
"    ]. Moreover, another study suggested that in male infants, TTN may be a marker of deficient pulmonary function reflecting inherited susceptibility to the development of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of TTN is usually at the time of birth and within two hours after delivery. Tachypnea (respiratory rate greater than 60 breaths per minute) is the most prominent feature. Infants with this condition typically have cyanosis and increased work of breathing, manifested by nasal flaring, mild intercostal and subcostal retractions, and expiratory grunting. The anterior-posterior diameter of the chest may be increased.",
"   </p>",
"   <p>",
"    Breath sounds in affected infants typically are clear, without rales or rhonchi. Infants with mild to moderate TTN are symptomatic for 12 to 24 hours, but signs may persist as long as 72 hours in severe cases. Infants rarely require a supplemental oxygen concentration greater than 40 percent to achieve adequate oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTN is a clinical diagnosis. Characteristic findings on chest radiograph support the diagnosis. They include increased lung volumes with flat diaphragms, mild cardiomegaly, and prominent vascular markings in a sunburst pattern originating at the hilum. Fluid often is seen in the interlobar fissures, and pleural effusions may be present. Alveolar edema may appear as fluffy densities.",
"   </p>",
"   <p>",
"    Arterial blood gas measurements typically reveal mild to moderate hypoxemia and mild hypercapnia, resulting in respiratory acidosis. Complete blood count and differential are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTN is a benign disorder, and pathologic conditions must be excluded. Because most of these disorders have overlapping clinical and radiological features, recent studies have looked for biochemical markers, such as endothelin-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] or atrial natriuretic peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/15\">",
"     15",
"    </a>",
"    ], which may aid in the differential diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonia or sepsis should be considered, especially in cases that persist longer than 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TTN is unlikely in infants who require persistently high oxygen concentration (greater than 60 percent) or mechanical ventilation.",
"     </li>",
"     <li>",
"      Affected infants also should be evaluated clinically for cardiac disease and further studies undertaken if it is suspected.",
"     </li>",
"     <li>",
"      TTN may complicate respiratory distress syndrome (RDS) in premature infants. However, infants with RDS usually have a characteristic chest radiograph and more significant requirements for respiratory support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because TTN is a benign, self-limited condition, management is supportive. Supplemental oxygen is provided by hood or nasal cannula to maintain oxygen saturation above 90 percent. Infants with TTN rarely require more than 40 percent inspired oxygen concentration. However, if the required supplemental oxygen concentration is greater or the infant has increased work of breathing as well as tachypnea, we sometimes use nasal continuous positive airway pressure (CPAP).",
"   </p>",
"   <p>",
"    Supportive measures include maintaining a neutral thermal environment and providing nutrition. Respiratory rates greater than 60 to 80 breaths per minute or increased work of breathing preclude oral feeding; orogastric tube feeding or intravenous fluids should be provided in such patients. If tachypnea persists longer than four to six hours or if the initial CBC and differential are abnormal, we obtain a blood culture and begin antibiotic coverage with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    while awaiting the results.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     Furosemide",
"    </a>",
"    does not affect the clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid restriction may be beneficial in the management of severe TTN. In a trial of 73 late preterm and term infants with TTN, post-hoc analysis demonstrated fluid restriction compared with standard therapy reduced the duration of respiratory support for the subset of patients (n = 26) who had severe TTN (defined as requiring respiratory support for &ge;48 hours) without any adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32804/abstract/19\">",
"     19",
"    </a>",
"    ]. For preterm infants, the standard fluid management consisted of an intake of 80",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    and restricted fluid therapy as 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for the first day of life. For term infants, standard therapy was 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    and restricted fluid therapy 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for the first day of life. However, further studies are needed to confirm whether or not fluid restriction is a safe and effective intervention for TTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/20/26945?source=see_link\">",
"       \"Patient information: Transient tachypnea of the newborn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient tachypnea of the newborn (TTN), a common cause of respiratory distress in the immediate newborn period, is a parenchymal lung disorder characterized by pulmonary edema resulting from delayed resorption and clearance of fetal alveolar fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for TTN include prematurity, birth by cesarean delivery, maternal diabetes, and maternal asthma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical presentation of TTN is onset of tachypnea within two hours after delivery. Infants may also be cyanotic and have increased work of breathing (ie, nasal flaring, intercostals and subcostal retractions, and expiratory grunting). Symptoms generally resolve after 12 to 24 hours but may persist as long as 72 hours in severe cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TTN is a benign disorder and other causes of neonatal respiratory distress must be excluded. The differential diagnosis of TTN includes pneumonia, sepsis, cardiac disease, and respiratory distress syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because TTN is a benign self-limited condition, management is supportive. It includes maintaining a neutral thermal environment, providing nutrition, and, if needed, administering supplemental oxygen. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/1\">",
"      Avery ME, Gatewood OB, Brumley G. Transient tachypnea of newborn. Possible delayed resorption of fluid at birth. Am J Dis Child 1966; 111:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/2\">",
"      Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/3\">",
"      Liem JJ, Huq SI, Ekuma O, et al. Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms. J Pediatr 2007; 151:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/4\">",
"      Bland RD, Nielson DW. Developmental changes in lung epithelial ion transport and liquid movement. Annu Rev Physiol 1992; 54:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/5\">",
"      O'Brodovich HM. Immature epithelial Na+ channel expression is one of the pathogenetic mechanisms leading to human neonatal respiratory distress syndrome. Proc Assoc Am Physicians 1996; 108:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/6\">",
"      Li Y, Marcoux MO, Gineste M, et al. Expression of water and ion transporters in tracheal aspirates from neonates with respiratory distress. Acta Paediatr 2009; 98:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/7\">",
"      Machado LU, Fiori HH, Baldisserotto M, et al. Surfactant deficiency in transient tachypnea of the newborn. J Pediatr 2011; 159:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/8\">",
"      Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol 2001; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/9\">",
"      Tutdibi E, Gries K, B&uuml;cheler M, et al. Impact of labor on outcomes in transient tachypnea of the newborn: population-based study. Pediatrics 2010; 125:e577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/10\">",
"      Kol&aring;s T, Saugstad OD, Daltveit AK, et al. Planned cesarean versus planned vaginal delivery at term: comparison of newborn infant outcomes. Am J Obstet Gynecol 2006; 195:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/11\">",
"      Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care 1998; 21 Suppl 2:B79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/12\">",
"      Pinter E, Peyman JA, Snow K, et al. Effects of maternal diabetes on fetal rat lung ion transport. Contribution of alveolar and bronchiolar epithelial cells to Na+,K(+)-ATPase expression. J Clin Invest 1991; 87:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/13\">",
"      Demissie K, Marcella SW, Breckenridge MB, Rhoads GG. Maternal asthma and transient tachypnea of the newborn. Pediatrics 1998; 102:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/14\">",
"      Birnkrant DJ, Picone C, Markowitz W, et al. Association of transient tachypnea of the newborn and childhood asthma. Pediatr Pulmonol 2006; 41:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/15\">",
"      Onal EE, Dilmen U, Adam B, et al. Serum atrial natriuretic peptide levels in infants with transient tachypnea of the newborn. J Matern Fetal Neonatal Med 2005; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/16\">",
"      Kuo CY, Chou YH, Lien R, Yang PH. Study of plasma endothelin-1 concentrations in Taiwanese neonates with respiratory distress. Chang Gung Med J 2001; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/17\">",
"      Wiswell TE, Rawlings JS, Smith FR, Goo ED. Effect of furosemide on the clinical course of transient tachypnea of the newborn. Pediatrics 1985; 75:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/18\">",
"      Lewis V, Whitelaw A. Furosemide for transient tachypnea of the newborn. Cochrane Database Syst Rev 2002; :CD003064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32804/abstract/19\">",
"      Stroustrup A, Trasande L, Holzman IR. Randomized controlled trial of restrictive fluid management in transient tachypnea of the newborn. J Pediatr 2012; 160:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5066 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-113.53.254.124-FD7A2DB3BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32804=[""].join("\n");
var outline_f32_2_32804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5066\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5066|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/45/18132\" title=\"figure 1\">",
"      NB lung fluid clearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/20/26945?source=related_link\">",
"      Patient information: Transient tachypnea of the newborn (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_2_32805="Lateral approach for lumbar puncture";
var content_f32_2_32805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Spinal needle access into the subarachnoid space by the median or lateral approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32805=[""].join("\n");
var outline_f32_2_32805=null;
var title_f32_2_32806="T cell NHL hemophagocytosis";
var content_f32_2_32806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large T cell lymphoma with reactive hemophagocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The red pulp of the spleen is diffusely permeated by large lymphoma cells (T lineage, blue arrows) and histiocytes showing erythrophagocytosis (black arrow). The histiocytes have smaller, bland-looking nuclei with delicate chromatin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32806=[""].join("\n");
var outline_f32_2_32806=null;
var title_f32_2_32807="Topotecan: Drug information";
var content_f32_2_32807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topotecan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/34/5670?source=see_link\">",
"    see \"Topotecan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/21/20822?source=see_link\">",
"    see \"Topotecan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;;",
"     </li>",
"     <li>",
"      Topotecan For Injection;",
"     </li>",
"     <li>",
"      Topotecan Hydrochloride For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Camptothecin;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Topoisomerase I Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted:",
"     <b>",
"      Note:",
"     </b>",
"     Baseline neutrophil count should be &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets should be &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to treatment; for retreatment, neutrophil count should be &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and hemoglobin &ge;9 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IVPB: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeated every 21 days, minimum of 4 cycles recommended in the absence of tumor progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeated every 21 days (round dose to the nearest 0.25 mg); if patient vomits after dose is administered, do not give a replacement dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metastatic ovarian cancer:",
"     </b>",
"     IVPB: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeated every 21 days, minimum of 4 cycles recommended in the absence of tumor progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer:",
"     </b>",
"     IVPB: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days (followed by cisplatin 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 only, [with hydration]); repeated every 21 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F229299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling recommends the following dosage adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Reduce to 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Insufficient data available for dosing recommendation (contraindicated in the Canadian labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For topotecan in combination with cisplatin for cervical cancer, do not initiate treatment in patients with serum creatinine &gt;1.5 mg/dL; consider discontinuing treatment in patients with serum creatinine &gt;1.5 mg/dL in subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Reduce dose to 1.8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Insufficient data available for dosing recommendation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007:",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Administer 50% of dose or reduce by 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose or reduce by 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995:",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 70% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F229300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Manufacturer&rsquo;s labeling recommends the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Bilirubin 1.7-15 mg/dL (U.S. labeling) or &gt;1.5-&lt;10 mg/dL (Canadian labeling): No adjustment necessary (the half-life is increased slightly; usual doses are generally tolerated).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Bilirubin &gt;1.5 mg/dL: No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3034534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovarian and small cell lung cancer: Dosage adjustment for hematological effects: Severe neutropenia (&lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce dose to 1.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider G-CSF support [beginning on day 6] prior to instituting dose reduction for severe neutropenia).",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling states that the dose may be further reduced to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervical cancer (cisplatin may also require dosage adjustment): Severe febrile neutropenia (&lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     with temperature of 38&deg;C) or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce topotecan to 0.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider G-CSF support [beginning on day 4] prior to instituting dose reduction for neutropenic fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For neutropenic fever despite G-CSF use, reduce dose to 0.45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Small cell lung cancer: Severe neutropenia (neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     associated with fever or infection or lasting &gt;7 days) or prolonged neutropenia (neutrophils &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     to &le;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     lasting beyond day 21) or platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or grades 3/4 diarrhea: Reduce dose by 0.4  mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider same dosage reduction for grade 2 diarrhea if clinically indicated).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hycamtin&reg;: 0.25 mg, 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hycamtin&reg;: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 1 mg/mL (4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F229274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer IVPB over 30 minutes. For combination chemotherapy with cisplatin, administer pretreatment hydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer without regard to meals. Swallow whole; do not crush, chew, or divide capsule. If vomiting occurs after dose, do not take replacement dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F229337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Carboplatin, cimetidine, cisplatin, cyclophosphamide, doxorubicin, etoposide, gemcitabine, granisetron, ifosfamide, methylprednisolone sodium succinate, metoclopramide, ondansetron, oxaliplatin, paclitaxel, palonosetron, prochlorperazine edisylate, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dexamethasone sodium phosphate, fluorouracil, mitomycin, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ticarcillin/clavulanate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic ovarian cancer, relapsed or refractory small cell lung cancer, recurrent or resistant (stage IVB) cervical cancer (in combination with cisplatin)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F229327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of central nervous system lesions (metastatic from lung cancer), central nervous system lymphoma (primary), Ewing&rsquo;s sarcoma, merkel cell cancer, osteosarcoma, rhabdomyosarcoma (pediatrics), neuroblastoma (pediatrics)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hycamtin&reg; may be confused with Mycamine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Topotecan may be confused with irinotecan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (6% to 29%), fever (5% to 28%), pain (5% to 23%), headache (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (10% to 49%), rash (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (8% to 64%), vomiting (10% to 45%), diarrhea (6% to 32%; Oral: grade 3: 4%; grade 4: &le;1%; onset: 9 days), constipation (5% to 29%), abdominal pain (5% to 22%), anorexia (7% to 19%), stomatitis (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (89% to 98%; grade 4: 7% to 37%; nadir: 15 days), neutropenia (83% to 97%; grade 4: 32% to 80%; nadir 12-15 days; duration: 7 days), leukopenia (86% to 97%; grade 4: 15% to 32%), thrombocytopenia (69% to 81%; grade 4: 6% to 27%; nadir: 15 days; duration: 3-5 days), neutropenic fever/sepsis (2% to 43%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (6% to 22%), cough (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Obstruction (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (transient; 8%; grades 3/4: 4%), bilirubin increased (grades 3/4: &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, anaphylactoid reactions, angioedema, bleeding (severe, associated with thrombocytopenia), dermatitis (severe), extravasation (inadvertent), interstitial lung disease (ILD), neutropenic colitis, pancytopenia, pruritus (severe)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to topotecan or any component of the formulation; severe bone marrow depression",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute); pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neutropenia, which may be severe or lead to infection or fatalities. Monitor blood counts frequently. Do NOT administer to patients with baseline neutrophils &lt;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      and platelets &lt;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      .",
"     </b>",
"     The dose-limiting toxicity is bone marrow suppression (primarily neutropenia); may also cause thrombocytopenia and anemia. Neutropenia is not cumulative over time. In a clinical study comparing I.V. to oral topotecan, G-CSF support was administered in a higher percentage of patients receiving oral topotecan (Eckardt, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Diarrhea has been reported with oral topotecan; may be severe (requiring hospitalization); educate patients on early recognition and proper management,   including diet changes, increase in fluid intake, antidiarrheals, and antibiotics. The incidence of diarrhea may be higher in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial lung disease (ILD): ILD (with fatalities) has been reported; monitor for signs/symptoms (eg, dyspnea, fever, cough, hypoxia) and discontinue use in patients with confirmed ILD. Risk factors for ILD include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and the use of colony-stimulating factors or medication with pulmonary toxicity. Monitor pulmonary symptoms (cough, fever, dyspnea, and/or hypoxia) and discontinue if ILD is diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenic colitis: Topotecan-induced neutropenia may lead to neutropenic colitis, including fatalities; should be considered in patients presenting with neutropenia, fever, and abdominal pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may require dose adjustment. Use in severe renal impairment is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; P-glycoprotein inhibitors: Topotecan exposure is increased when oral topotecan is used concurrently with P-glycoprotein inhibitors; avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent - use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCRP/ABCG2 Inhibitors: May increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Filgrastim: May enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies found embryotoxicity, fetotoxicity, reduced fetal body weight, and teratogenicity including eye, brain, skull, and vertebrae malformations. May cause fetal harm in pregnant women. Women of childbearing potential should use effective contraception to prevent pregnancy during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5441000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding should be discontinued in women who are receiving topotecan.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5443707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hycamtin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (10): $1009.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (10): $4039.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Topotecan HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/4 mL (4 mL): $288.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Hycamtin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (1): $1348.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Topotecan HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (1): $432.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, renal function tests, bilirubin; monitor for symptoms of interstitial lung disease",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin (AR, AT, AU, BE, BG, BR, CH, CL, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PH, PK, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Oncotecam (PY);",
"     </li>",
"     <li>",
"      Oncotecan (CO, EC, PE);",
"     </li>",
"     <li>",
"      Topodria (CO);",
"     </li>",
"     <li>",
"      Topokebir (AR);",
"     </li>",
"     <li>",
"      Topotel (IN, PH, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to topoisomerase I and stabilizes the cleavable complex so that religation of the cleaved DNA strand cannot occur. This results in the accumulation of cleavable complexes and single-strand DNA breaks. Topotecan acts in S phase of the cell cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     of the lactone is high (mean: 87.3 L/mm",
"     <sup>",
"      2",
"     </sup>",
"     ; range: 25.6-186 L/mm",
"     <sup>",
"      2",
"     </sup>",
"     ), suggesting wide distribution and/or tissue sequestering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes a rapid, pH-dependent hydrolysis of the lactone ring to yield a relatively inactive hydroxy acid in plasma; metabolized in the liver to N-demethylated metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 2-3 hours; renal impairment: 5 hours; Oral: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 1-2 hours; delayed with high-fat meal (3-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Urine (51%; 3% as N-desmethyl topotecan); feces (18%; 2% as N-desmethyl topotecan)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Urine (20%; 2% as N-desmethyl topotecan); feces (33%; &lt;2% as N-desmethyl topotecan)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 102, 174.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Craig SB, Bhatt UH, and Patel K, &ldquo;Stability and Compatibility of Topotecan Hydrochloride for Injection With Common Infusion Solutions and Containers,&rdquo;",
"      <i>",
"       J Pharm Biomed Anal",
"      </i>",
"      , 1997, 16(2):199-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/9408834/pubmed\" id=\"9408834\" target=\"_blank\">",
"        9408834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eckardt JR, von Pawel J, Pujol JL, et al, &ldquo;Phase III Study of Oral Compared With Intravenous Topotecan as Second-Line Therapy in Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(15):2086-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/17513814/pubmed\" id=\"17513814\" target=\"_blank\">",
"        17513814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gronlund B, Hansen HH, Hogdall C, et al, &ldquo;Efficacy of Low-Dose Topotecan in Second-Line Treatment for Patients With Epithelial Ovarian Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(8):1656-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/12365013/pubmed\" id=\"12365013\" target=\"_blank\">",
"        12365013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoskins P, Vergote I, Cervantes A, et al, &ldquo;Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2010, 102(20):1547-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/20937992/pubmed\" id=\"20937992\" target=\"_blank\">",
"        20937992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunold A, Weddeling N, Paulussen M, et al, \"Topotecan and Cyclophosphamide in Patients With Refractory or Relapsed Ewing Tumors,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(6):795-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/16411206/pubmed\" id=\"16411206\" target=\"_blank\">",
"        16411206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korfel A, Oehm C, von Pawel J, et al, &ldquo;Response to Topotecan of Symptomatic Brain Metastases of Small-Cell Lung Cancer Also After Whole-Brain Irradiation. a Multicentre Phase II Study,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2002, 38(13):1724-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/12175688/pubmed\" id=\"12175688\" target=\"_blank\">",
"        12175688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kruijtzer CMF, Beijnen JH, Rosing H, et al, &ldquo;Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(13):2943-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/12089223/pubmed\" id=\"12089223\" target=\"_blank\">",
"        12089223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy T, Inbar M, Menczer J, et al, \"Phase II Study of Weekly Topotecan in Patients With Recurrent or Persistent Epithelial Ovarian Cancer,\"",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 95(3):686-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/15581982/pubmed\" id=\"15581982\" target=\"_blank\">",
"        15581982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      London WB, Frantz CN, Campbell LA, et al, &ldquo;Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(24):3808-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/20660830/pubmed\" id=\"20660830\" target=\"_blank\">",
"        20660830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Long HJ 3rd, Bundy BN, Grendys EC Jr, et al, &ldquo;Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(21):4626-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/15911865/pubmed\" id=\"15911865\" target=\"_blank\">",
"        15911865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathijssen RH, Loos WJ, Verweij J, et al, &ldquo;Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan,&rdquo;",
"      <i>",
"       Curr Cancer Drug Targets",
"      </i>",
"      , 2002, 2(2):103-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/12188913/pubmed\" id=\"12188913\" target=\"_blank\">",
"        12188913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Sill MW, McMeekin DS, et al, \"Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4649-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/19720909/pubmed\" id=\"19720909\" target=\"_blank\">",
"        19720909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muderspach LI, Blessing JA, Levenback C, et al, &ldquo;A Phase II Study of Topotecan in Patients with Squamous Cell Carcinoma of the Cervix:  A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gyn Oncol",
"      </i>",
"      , 2001, 81(2):213-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/11354055/pubmed\" id=\"11354055\" target=\"_blank\">",
"        11354055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Brien ME, Ciuleanu TE, Tsekov H, et al, &ldquo;Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(34):5441-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/17135646/pubmed\" id=\"17135646\" target=\"_blank\">",
"        17135646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Reilly S, Rowinsky EK, Slichenmyer W, et al, &ldquo;Phase I and Pharmacologic Study of Topotecan in Patients With Impaired Hepatic Function,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 1996, 88(12):817-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/8637048 /pubmed\" id=\"8637048 \" target=\"_blank\">",
"        8637048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Reilly S, Rowinsky EK, Slichenmyer W, et al, &ldquo;Phase I and Pharmacologic Study of Topotecan in Patients With Impaired Renal Function,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(12):3062-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/8955651/pubmed\" id=\"8955651\" target=\"_blank\">",
"        8955651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saylors RL 3rd, Stine KC, Sullivan J, et al, &ldquo;Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(15):3463-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/11481351/pubmed\" id=\"11481351\" target=\"_blank\">",
"        11481351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tai P, Yu E, Assouline A, et al, &ldquo;Multimodality Management for 145 Cases of Merkel Cell Carcinoma,&rdquo;",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2010, 27(4):1260-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/19949898/pubmed\" id=\"19949898\" target=\"_blank\">",
"        19949898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Voloschin AD, Betensky R, Wen PY, et al, &ldquo;Topotecan as Salvage Therapy for Relapsed or Refractory Primary Central Nervous System Lymphoma,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2008, 86(2):211-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/2/32807/abstract-text/17896078/pubmed\" id=\"17896078\" target=\"_blank\">",
"        17896078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10007 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32807=[""].join("\n");
var outline_f32_2_32807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708912\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229294\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229331\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229297\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229298\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229299\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229300\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034534\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229271\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229256\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229274\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229337\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229272\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229327\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229339\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229329\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229277\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229260\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300156\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229264\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229289\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229306\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5441000\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5443707\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324004\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229269\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038846\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229259\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229276\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/34/5670?source=related_link\">",
"      Topotecan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/21/20822?source=related_link\">",
"      Topotecan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_2_32808="Expectant management of severe preeclampsia";
var content_f32_2_32808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Expectant management of severe preeclampsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Edmund F Funai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32808/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/2/32808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia refers to the new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"mobipreview.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ). The disease is considered severe when any of the features listed in the following table are present (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"mobipreview.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A database of hospital discharge data from approximately 300,000 deliveries in the United States found the overall incidence of severe preeclampsia was about 1 percent of all pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/1\">",
"     1",
"    </a>",
"    ]. Studies limited to nulliparous women report that about 5 percent develop preeclampsia and 40 to 50 percent of these women develop severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The incidence of severe preeclampsia at &lt;34 weeks is 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with severe preeclampsia are usually delivered promptly to prevent maternal and fetal complications. Since the disease is progressive and there is no medical treatment, delivery is always in the best interest of the mother. However, preterm delivery is not always in the best interest of the fetus; therefore, a decision to delay delivery can be considered under certain circumstances.",
"   </p>",
"   <p>",
"    The rationale for delaying delivery in these pregnancies is to reduce perinatal morbidity and mortality by delivery of a more mature fetus and, to a lesser degree, to achieve a more favorable cervix for vaginal birth. The risk of prolonging pregnancy is worsening maternal endothelial dysfunction and continued poor perfusion of major maternal organs with the potential for severe end organ damage to the brain, liver, kidneys,",
"    <span class=\"nowrap\">",
"     placenta/fetus,",
"    </span>",
"    and hematologic and vascular systems.",
"   </p>",
"   <p>",
"    This topic will discuss issues that should be considered in selecting women with severe preeclampsia for prompt delivery versus expectant management. The general management of pregnancies complicated by preeclampsia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2262698\">",
"    <span class=\"h1\">",
"     OUTCOME OF PREGNANCIES COMPLICATED BY SEVERE PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A literature review including 72 publications reported the following serious maternal complications of severe preeclampsia: seizures, pulmonary edema, hypertensive encephalopathy, stroke, renal failure, hepatic failure or rupture, retinal detachment or cortical blindness, disseminated intravascular coagulation, placental abruption, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of increased morbidity associated with preeclamptic pregnancies was best illustrated in a controlled study that compared the pregnancy outcome of 319 women with mild or severe preeclampsia delivering their first baby to that of 3229 similar women whose blood pressure remained normal during the pregnancy (",
"    <a class=\"graphic graphic_table graphicRef54736 \" href=\"mobipreview.htm?29/31/30204\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/6\">",
"     6",
"    </a>",
"    ]. The major consequences of severe preeclampsia were increased rates of maternal liver and kidney dysfunction, induced labor, cesarean delivery, preterm birth, fetal growth restriction, and neonatal respiratory problems. The highest risk of maternal and neonatal morbidity was in pregnancies complicated by severe second trimester preeclampsia. In this series, there was no significant increase in the rate of fetal or neonatal death, but others have found that earlier onset of severe preeclampsia and severely restricted fetal growth are associated with a dismal neonatal prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2262705\">",
"    <span class=\"h2\">",
"     Onset at less than 24.0 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both maternal and fetal outcomes are poor with expectant management of severe preeclampsia with onset in the second trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Twenty-five to 63 percent of mothers managed expectantly had serious complications, including HELLP syndrome, renal insufficiency, abruptio placentae, pulmonary edema, and eclampsia.",
"   </p>",
"   <p>",
"    The following perinatal survival rates by week of gestation were derived from combined data from several series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      less than 23 and",
"      <span class=\"nowrap\">",
"       0/7ths",
"      </span>",
"      weeks (28 fetuses, 0 survivors)",
"     </li>",
"     <li>",
"      23 and 0 to",
"      <span class=\"nowrap\">",
"       6/7ths",
"      </span>",
"      weeks (22 fetuses, 18 percent survival)",
"     </li>",
"     <li>",
"      24 and 0 to",
"      <span class=\"nowrap\">",
"       6/7ths",
"      </span>",
"      weeks (26 fetuses, 58 percent survival)",
"     </li>",
"     <li>",
"      25 and 0 to",
"      <span class=\"nowrap\">",
"       6/7ths",
"      </span>",
"      weeks (27 fetuses, 70 percent survival)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survivors are at high risk of short-term complications and long-term disability. However, the limits of viability vary among hospitals and are impacted by factors other than gestational age, such as gender, birthweight, and administration of antenatal corticosteroids, and these factors should be taken into account when counseling individual patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2262712\">",
"    <span class=\"h2\">",
"     Randomized trials involving pregnancies &ge;28 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of various management approaches of early third trimester severe preeclampsia was evaluated in two small randomized trials that assigned women with severe preeclampsia to aggressive or expectant management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The pregnancies were at 28 to 32 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/11\">",
"     11",
"    </a>",
"    ] and 28 to 34 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10\">",
"     10",
"    </a>",
"    ] weeks of gestation and the diagnosis of severe preeclampsia was based on blood pressure criteria alone.",
"   </p>",
"   <p>",
"    Both trials reported significant prolongation of pregnancy and improvement in neonatal outcome with expectant management, with no increase in the rate of maternal complications. Prolongation of pregnancy averaged 15.4 days (range 4 to 36 days) in the larger of these trials (n = 95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/11\">",
"     11",
"    </a>",
"    ] and 7.1 days in the smaller series (n = 38) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10\">",
"     10",
"    </a>",
"    ]. In the larger trial, there were no cases of eclampsia or perinatal death and no increase in the frequency of abruptio placentae with expectant management (incidence of abruption: 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/11\">",
"     11",
"    </a>",
"    ]. Importantly, infants in the expectantly managed group had a significantly higher gestational age at delivery (32.9 versus 30.8 weeks) and birth weight, lower incidence of admission to the neonatal intensive care unit (76 versus 100 percent), and lower incidence of neonatal complications (respiratory distress 22 versus 50 percent; necrotizing enterocolitis 0 versus 11 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2262719\">",
"    <span class=\"h2\">",
"     Systematic review of studies of pregnancies &lt;34 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials and studies of severe preeclampsia &lt;34 weeks of gestation (39 cohorts, 4650 women) concluded expectant management was associated with pregnancy prolongation of 7 to 14 days and a median serious maternal complication rate of &lt;5 percent, which is similar to the rate with prompt intervention (2 studies, 42 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/5\">",
"     5",
"    </a>",
"    ]. One&ndash;half of expectantly managed patients delivered for maternal indications and the other half delivered for fetal indications.",
"   </p>",
"   <p>",
"    Approximately 40 percent of women with severe preeclampsia at &lt;34 weeks of gestation were appropriate candidates for expectant management rather than delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2263105\">",
"     'Candidates for expectant management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13443830\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of pregnancies complicated by severe preeclampsia, growth restriction, and preterm birth was illustrated by the Pre-eclampsia Eclampsia Trial Amsterdam (PETRA) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/12\">",
"     12",
"    </a>",
"    ]. This study assessed neurodevelopmental outcome at age 4.5 years in 216 children born after expectant management of severe hypertensive complications of pregnancy with onset between 24 and 34 weeks of gestation. All of the children were products of singleton gestations complicated by pregnancy-induced hypertension, severe preeclampsia, HELLP, or eclampsia; 91 percent were small for gestational age at birth; and the mean gestational age at delivery was 31.4 weeks. At 4.5 years corrected age, there was an increased frequency of IQ that was subnormal (78 to 93) or abnormal (&lt;78) (30 percent versus 16 percent in the general population). Fifty-four percent of the children had normal results on all tests of developmental outcome. Seven percent of the children were attending special education classes, which is about seven times as many as the nationwide rate of 1 percent at that age in The Netherlands. There were no blind or deaf children in the cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2262726\">",
"    <span class=\"h1\">",
"     GESTATIONAL AGE BASED APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the outcome data presented above, if a woman develops severe preeclampsia before 24 weeks of gestation, we often recommend termination of pregnancy to reduce the mother's risk of developing life-threatening morbidity (eg, cerebrovascular hemorrhage) and to prevent the birth of an infant at the limit of viability, and thus at high risk of death or severe permanent disability. Factors critical in making this decision are the estimated fetal weight, presence or absence of growth restriction, and the neonatologist's judgment of the neonatal prognosis. If the fetus is deemed nonviable, we recommend delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At 24 to 25 weeks of gestation, the decision making process is exceptionally complex; the clinician and patient should carefully weigh the risks and benefits of expectant management, taking into account individual clinical factors such as the estimated fetal weight and whether a full course of corticosteroids can",
"    <span class=\"nowrap\">",
"     be/has",
"    </span>",
"    been administered.",
"   </p>",
"   <p>",
"    Between 25 and 34 weeks of gestation, we offer expectant management to appropriately selected women, as described below. (See",
"    <a class=\"local\" href=\"#H2263105\">",
"     'Candidates for expectant management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest delivery for all women with severe preeclampsia who have reached a favorable gestational age (34 or more weeks of gestation), as prolonging the pregnancy at this gestational age subjects the mother and fetus to significant risks with relatively small potential benefits. This is consistent with recommendations by expert groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263105\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management of severe preeclampsia is a reasonable approach for some patients. It should be emphasized that expectant management of severe preeclampsia is not associated with any direct maternal benefits. The mother is taking on a small but significant risk to her own health, with a view to delay delivery until a more favorable gestational age is reached for her child. These patients should be hospitalized and cared for by, or in consultation with, a maternal-fetal medicine specialist. In this environment, we offer expectant management for patients with severe preeclampsia presenting between 24 and 34 weeks of gestation in the following circumstances:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263112\">",
"    <span class=\"h2\">",
"     Transient laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic women with severe preeclampsia by laboratory criteria alone (ALT or AST twice the upper limit of normal, platelet count of less than 100,000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    may be managed expectantly if the abnormalities resolve within 24 to 48 hours of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In otherwise asymptomatic or mildly hypertensive women, it is reasonable to delay delivery, administer antenatal glucocorticoids, and repeat the laboratory tests (AST, ALT, platelet count) every 6 to 12 hours to see if they improve.",
"   </p>",
"   <p>",
"    We would promptly deliver patients with worsening of liver function tests or platelet counts over a period of 6 to 12 hours, and those who develop other signs of severe preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263119\">",
"    <span class=\"h2\">",
"     Severe preeclampsia based solely on proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of other features of severe preeclampsia, proteinuria greater than 5",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours alone is not an indication for delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/4\">",
"     4",
"    </a>",
"    ]. For this reason, once the threshold of 300",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours for the diagnosis of preeclampsia has been exceeded, we do not obtain repeated 24-hour urinary protein estimations.",
"   </p>",
"   <p>",
"    This recommendation is supported by a systematic review of studies of proteinuria as a predictor of pregnancy outcome (16 studies, 6749 women) that found even high levels of proteinuria had poor positive and negative likelihood ratios with wide confidence intervals for prediction of major maternal, fetal, and neonatal complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/15\">",
"     15",
"    </a>",
"    ]. The authors concluded that determining the level of proteinuria was not a clinically useful test for management of preeclamptic pregnancies. They also stated well-designed prospective studies were needed due to heterogeneity in existing studies with respect to population, definition of preeclampsia, methods of measuring proteinuria, test thresholds, frequency of testing, interval between the test and outcome, reference standards, and the possibility of confounding by other risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263126\">",
"    <span class=\"h2\">",
"     Severe preeclampsia based solely on fetal growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We offer expectant management to women whose only criterion for severe preeclampsia is the presence of fetal growth restriction (FGR) if they meet the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild FGR, defined as an estimated fetal weight &ge;5th percentile and &lt;10th percentile for gestational age",
"     </li>",
"     <li>",
"      Gestational age less than 32 weeks",
"     </li>",
"     <li>",
"      Reassuring fetal testing, defined as a reassuring nonstress test, adequate amniotic fluid volume (amniotic fluid index [AFI] &gt;5.0 cm or maximal vertical pocket &gt;2.0 cm), and no persistent absent or reversed diastolic flow on umbilical artery Doppler velocimetry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These women should be admitted to the hospital for close maternal surveillance and daily fetal testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the admission-to-delivery interval in such pregnancies averages only three days, and over 85 percent of such women will require delivery within one week of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of fetal demise is increased when FGR is severe (fetal weight less than the 5th percentile) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/9,18,19\">",
"     9,18,19",
"    </a>",
"    ]. It is unclear whether these fetuses benefit from expectant management; we would deliver such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263133\">",
"    <span class=\"h2\">",
"     Severe preeclampsia based solely on blood pressure criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have established a precedent for expectant management of patients with severe preeclampsia by blood pressure criteria alone in pregnancies 28 to 34 weeks with reassuring fetal testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Antihypertensive agents are given to control severe hypertension.",
"   </p>",
"   <p>",
"    The use of antihypertensive drugs does not alter the course of preeclampsia or reduce perinatal morbidity or mortality, and their use may diminish uteroplacental perfusion or mask an increase in blood pressure, which can be a sensitive measure of worsening disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. For these reasons, treatment of mild hypertension during pregnancy is not generally recommended; however, antihypertensive agents should be used in women with severe hypertension to prevent a cerebrovascular accident. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2263344\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some clinical situations, we feel the risks associated with expectant management outweigh any potential benefits. Under these circumstances, we intervene regardless of gestational age and even if the second corticosteroid dose has not been given or the maximum therapeutic effect has not been achieved.",
"   </p>",
"   <p>",
"    Strong consideration should be given to abandoning expectant management and proceeding with prompt delivery if any of the following conditions are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal hemodynamic instability (shock)",
"     </li>",
"     <li>",
"      Nonreassuring fetal testing (nonreassuring nonstress test or biophysical profile score, estimated fetal weight less than the fifth percentile for gestational age, oligohydramnios with AFI &lt;5.0 cm or maximal vertical pocket &lt;2.0 cm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent absent or reversed diastolic flow on umbilical artery Doppler velocimetry)",
"     </li>",
"     <li>",
"      Persistent severe hypertension unresponsive to medical therapy",
"     </li>",
"     <li>",
"      Severe headache (ie, incapacitating, \"the worst headache of my life\") or persistent progressive headache (despite analgesia), visual aberrations, or",
"      <span class=\"nowrap\">",
"       epigastric/right",
"      </span>",
"      upper quadrant pain",
"     </li>",
"     <li>",
"      Eclampsia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary edema",
"     </li>",
"     <li>",
"      Renal failure with a marked rise in serum creatinine (eg, rise in serum creatinine concentration by &ge;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      over baseline)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine output less than 0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"      for two hours unresponsive to hydration with two intravenous boluses of 500 mL fluid",
"     </li>",
"     <li>",
"      Abruptio placentae",
"     </li>",
"     <li>",
"      Laboratory abnormalities, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aminotransferases increasing over 6 to 12 hours and reaching levels twice the upper limit of normal",
"     </li>",
"     <li>",
"      Progressive decrease in platelet count to less than 100,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Coagulopathy in the absence of an alternative explanation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preterm labor",
"     </li>",
"     <li>",
"      Preterm premature rupture of membranes",
"     </li>",
"     <li>",
"      Maternal request for immediate delivery",
"     </li>",
"     <li>",
"      HELLP syndrome &mdash; Although some studies have reported that serious maternal complications in the setting of expectant management of HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) are uncommon with careful maternal monitoring, the benefit of expectant management in this setting has not been demonstrated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. The aim of expectant management is to improve neonatal morbidity and mortality; there is no evidence that overall perinatal outcome is improved with expectant management of HELLP compared to pregnancies delivered after a course of glucocorticoids. We consider expectant management in this setting an investigational approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT OF WOMEN WITH SEVERE PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with suspected preeclampsia should be admitted to the hospital to confirm the diagnosis, assess severity, monitor maternal and fetal status, and initiate supportive therapy or perform delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our initial management of these pregnancies involves:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Admission to the Labor and Delivery Unit. The patient may need to be monitored in this intensive setting for as long as 48 hours. She can be transferred to less intensive care when her blood pressure is stable without labile elevations into the severe range, her laboratory tests are stable or improving, and fetal testing is reassuring.",
"     </li>",
"     <li>",
"      Administration of a course of antenatal corticosteroids &mdash; Reasonable efforts should be made to delay delivery for 48 hours to complete a full course of steroids. However, intervention will be necessary if there is deterioration in maternal or fetal status.",
"      <br/>",
"      <br/>",
"      Although some studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/26\">",
"       26",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/27\">",
"       27",
"      </a>",
"      ], have reported that neonates from preeclamptic pregnancies have a reduced incidence of respiratory distress syndrome and intraventricular hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/28\">",
"       28",
"      </a>",
"      ] compared to infants from normotensive pregnancies, this is not sufficient justification to withhold antenatal corticosteroid therapy if indicated by gestational age because corticosteroid therapy significantly reduces neonatal morbidity and mortality in these neonates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. A meta-analysis of randomized trials of antenatal corticosteroid treatment versus no antenatal corticosteroid treatment of pregnancies complicated by hypertension syndromes showed that treatment significantly reduced the risks of neonatal death (RR 0.50, 95% CI 0.29-0.87, two studies, 278 infants), respiratory distress syndrome (RR 0.50, 95% CI 0.35-0.72, five studies, 382 infants) and intraventricular hemorrhage (RR 0.38, 95% CI 0.17-0.87, two studies, 278 infants) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Antepartum or postpartum administration of corticosteroids does not reduce the severity or duration of severe preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizure prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link&amp;anchor=H16#H16\">",
"       \"Preeclampsia: Management and prognosis\", section on 'Seizure prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood pressure monitoring at least every one to two hours. Severe hypertension should be treated to reduce the risk of maternal cardiovascular complications. There is no consensus on what the threshold for treatment should be or how the threshold should vary by patient specific factors. We treat patients with systolic blood pressure &ge;150 mm Hg or the diastolic blood pressure &ge;95 to 100 mmHg. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of hypertension in pregnant and postpartum women\", section on 'Preeclampsia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Accurate recording of fluid intake and urine output.",
"     </li>",
"     <li>",
"      Laboratory studies &mdash; We obtain a complete blood count (including platelet count and smear), electrolytes, creatinine, alanine and aspartate aminotransferase (ALT, AST), and lactic acid dehydrogenase (LDH) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/34\">",
"       34",
"      </a>",
"      ]. Albumin can be useful to help guide nutritional replacement in cases of severe proteinuria. A coagulopathy profile (PT, PTT, fibrinogen) is sent if the ALT and AST are more than twice normal, if the platelet count is less than 100,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      or if placental abruption is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of fetal well-being, including a nonstress test, amniotic fluid volume determination, and estimation of fetal growth. We obtain umbilical artery Doppler velocimetry if fetal growth restriction or oligohydramnios is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPONENTS OF EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there are no contraindications to expectant management, we suggest the following regimen to minimize the risk of maternal and fetal complications. Close supervision of mother and fetus is crucial, as it is impossible to predict the clinical course the disease will take after admission, and clinical deterioration can occur rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/35\">",
"     35",
"    </a>",
"    ]. After initial assessment and stabilization on the Labor and Delivery Unit, these patients are monitored and medically managed on an antepartum unit. There are no data from randomized trials on which to base an evidence-based protocol for managing these patients. Our general approach to management on the antepartum unit is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalize until delivery. Findings from frequent maternal and fetal assessment are reviewed throughout the day and the ongoing risks of conservative management versus the benefit of further fetal maturation are reevaluated frequently.",
"     </li>",
"     <li>",
"      Monitor blood pressure every four hours. We do not awaken patients at night to check blood pressure if they are asymptomatic and blood pressure has been well-controlled during the day. Antihypertensive therapy is given to women with chronic hypertension and those being managed according to standard protocols for severe preeclampsia by blood pressure criteria only remote from term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frequently assess maternal symptoms (eg, headache, vision changes, epigastric or abdominal pain, decreased fetal activity, vaginal bleeding)",
"     </li>",
"     <li>",
"      Accurately record fluid intake and urine output to identify oliguria.",
"     </li>",
"     <li>",
"      Obtain a complete blood count, serum creatinine, and liver function tests at least twice weekly. Delivery should be considered if laboratory abnormalities worsen after an initial improvement.",
"     </li>",
"     <li>",
"      Finish the course of antenatal corticosteroids, if not already completed.",
"     </li>",
"     <li>",
"      Regularly assess fetal well-being. There is no standardized protocol for fetal assessment in this setting. We obtain fetal kick counts and nonstress tests at least daily, ultrasound assessment of amniotic fluid volume once or twice per week, weekly Doppler velocimetry of the umbilical artery if growth is abnormal, and ultrasound estimation of fetal growth every 7 to 14 days. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link\">",
"       \"Antepartum fetal heart rate assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=see_link\">",
"       \"Assessment of amniotic fluid volume\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continue",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      seizure prophylaxis until completion of the course of antenatal corticosteroids. If the patient remains a candidate for expectant management at that time, the magnesium sulfate can be discontinued until her status changes and preterm delivery becomes indicated.",
"     </li>",
"     <li>",
"      Consultation with neonatology and anesthesiology services.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several management strategies with no proven benefit in the setting of severe preeclampsia are commonly recommended, but are best avoided because of potential morbidity, cost,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient inconvenience. These include: routine use of continuous fetal heart rate monitoring, routine initiation of antihypertensive therapy, antepartum administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    seizure prophylaxis for over 48 hours, serial 24-hour urine collections for protein quantitation, and routine assessment of fetal lung maturity. However, the latter may be useful in delivery decisions between 30 and 34 weeks when there is contradictory or equivocal evidence of maternal or fetal deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery in the setting of severe preeclampsia will usually be initiated for the maternal indications described above, which include persistent signs or symptoms of end-organ damage, such as severe headache, epigastric pain, visual abnormality, uncontrollable hypertension, eclampsia, pulmonary edema, renal failure, severe thrombocytopenia, HELLP syndrome, and altered mental state. (See",
"    <a class=\"local\" href=\"#H2263344\">",
"     'Contraindications to expectant management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our opinion, fetal indications for intervention include nonreassuring fetal heart rate or biophysical testing, estimated fetal weight less than the fifth percentile for gestational age, oligohydramnios (defined as AFI &lt;5.0 cm or maximal vertical pocket &lt;2.0 cm),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent absent or reversed diastolic flow on umbilical artery Doppler velocimetry. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstetrical indications for delivery in patients with severe preeclampsia include preterm labor, preterm premature rupture of membranes, abruptio placentae, and fetal demise.",
"   </p>",
"   <p>",
"    In the absence of any of these maternal or fetal indications for earlier intervention, we deliver women hospitalized for expectant management of severe preeclampsia at 34 weeks of gestation. We do not assess fetal lung maturity prior to delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is reserved for standard obstetrical indications. A decision to expedite delivery in the setting of severe preeclampsia does not mandate immediate cesarean birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/36\">",
"     36",
"    </a>",
"    ]. Cervical ripening agents may be used if the cervix is not favorable prior to induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/37\">",
"     37",
"    </a>",
"    ]; however, a prolonged induction is best avoided.",
"   </p>",
"   <p>",
"    The safety of induction was illustrated by two retrospective series that compared neonatal outcome of over 700 singleton, live born, premature infants of women with severe preeclampsia who underwent induction or scheduled cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Induction was not associated with a significant increase in the rate of any major neonatal complication (respiratory distress syndrome, intraventricular hemorrhage, seizures, sepsis, death).",
"   </p>",
"   <p>",
"    At &ge;32 weeks of gestation, the rate of vaginal delivery after labor induction exceeds 60 percent, but at &le;28 weeks, it falls to 0 to 32 percent because of the high frequency of nonreassuring fetal heart rate tracings and failure of the cervix to dilate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. For this reason, some experts recommend scheduled cesarean delivery for women with severe preeclampsia who are under 28 to 30 weeks of gestation, especially if they have a low Bishop score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32808/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. We generally agree, but take parity and prior labor course into consideration, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest neuraxial anesthesia for women with adequate platelet counts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link&amp;anchor=H12561208#H12561208\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Neuraxial analgesia and low platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preeclampsia (",
"      <a class=\"graphic graphic_table graphicRef79977 \" href=\"mobipreview.htm?4/31/4603\">",
"       table 1",
"      </a>",
"      ) is severe when any features from the following table are present (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"mobipreview.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After thorough initial assessment, expectant management with aggressive maternal and fetal monitoring of appropriately selected women can improve perinatal outcome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial management of women with severe preeclampsia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2263105\">",
"       'Candidates for expectant management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2263344\">",
"       'Contraindications to expectant management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women managed expectantly should be hospitalized and cared for by, or in consultation with, a maternal-fetal medicine specialist. They should undergo daily maternal and fetal assessment with continual review of the ongoing risks of conservative management. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Components of expectant management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies &ge;34.0 weeks of gestation, we suggest prompt delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). At this gestational age, the maternal and fetal risks of prolonging the pregnancy generally outweigh the benefits of further fetal and cervical maturation. (See",
"      <a class=\"local\" href=\"#H2262698\">",
"       'Outcome of pregnancies complicated by severe preeclampsia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2262726\">",
"       'Gestational age based approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies between 24.0 and 34.0 weeks of gestation, we suggest expectant management in the following settings: (See",
"      <a class=\"local\" href=\"#H2262698\">",
"       'Outcome of pregnancies complicated by severe preeclampsia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2262726\">",
"       'Gestational age based approach to management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Laboratory abnormalities that are transient (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe proteinuria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or fetal growth restriction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) or severe hypertension (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) as the only criterion for severe disease.",
"      <br/>",
"      <br/>",
"      Prompt delivery is indicated if maternal or fetal status deteriorates during expectant management. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2263344\">",
"       'Contraindications to expectant management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pregnancies &lt;24.0 weeks of gestation, we suggest prompt delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Expectant management is associated with a high risk of severe maternal morbidity, perinatal mortality, and severe neonatal morbidity. (See",
"      <a class=\"local\" href=\"#H2262698\">",
"       'Outcome of pregnancies complicated by severe preeclampsia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2262726\">",
"       'Gestational age based approach to management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/1\">",
"      Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/2\">",
"      Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/3\">",
"      Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/4\">",
"      Publications Committee, Society for Maternal-Fetal Medicine. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011; 205:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/5\">",
"      Magee LA, Yong PJ, Espinosa V, et al. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancy 2009; 28:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/6\">",
"      Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/7\">",
"      Bombrys AE, Barton JR, Nowacki EA, et al. Expectant management of severe preeclampsia at less than 27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008; 199:247.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/8\">",
"      Jenkins SM, Head BB, Hauth JC. Severe preeclampsia at &lt;25 weeks of gestation: maternal and neonatal outcomes. Am J Obstet Gynecol 2002; 186:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/9\">",
"      Belghiti J, Kayem G, Tsatsaris V, et al. Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol 2011; 205:465.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/10\">",
"      Odendaal HJ, Pattinson RC, Bam R, et al. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 1990; 76:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/11\">",
"      Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/12\">",
"      van Wassenaer AG, Westera J, van Schie PE, et al. Outcome at 4.5 years of children born after expectant management of early-onset hypertensive disorders of pregnancy. Am J Obstet Gynecol 2011; 204:510.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/13\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/14\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/15\">",
"      Thangaratinam S, Coomarasamy A, O'Mahony F, et al. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med 2009; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/16\">",
"      Chammas MF, Nguyen TM, Li MA, et al. Expectant management of severe preterm preeclampsia: is intrauterine growth restriction an indication for immediate delivery? Am J Obstet Gynecol 2000; 183:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/17\">",
"      Chari RS, Friedman SA, O'Brien JM, Sibai BM. Daily antenatal testing in women with severe preeclampsia. Am J Obstet Gynecol 1995; 173:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/18\">",
"      Haddad B, Kayem G, Deis S, Sibai BM. Are perinatal and maternal outcomes different during expectant management of severe preeclampsia in the presence of intrauterine growth restriction? Am J Obstet Gynecol 2007; 196:237.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/19\">",
"      Witlin AG, Saade GR, Mattar F, Sibai BM. Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000; 182:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/20\">",
"      Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/21\">",
"      Sibai BM, Barton JR, Akl S, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992; 167:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/22\">",
"      Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007; 196:514.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/23\">",
"      Visser W, Wallenburg HC. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 1995; 102:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/24\">",
"      van Pampus MG, Wolf H, Westenberg SM, et al. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/25\">",
"      Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/26\">",
"      Shah DM, Shenai JP, Vaughn WK. Neonatal outcome of premature infants of mothers with preeclampsia. J Perinatol 1995; 15:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/27\">",
"      Carvalho MA, Fa&uacute;ndes A, Santos LC. Pregnancy-induced hypertension and hyaline membrane disease. Int J Gynaecol Obstet 1997; 58:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/28\">",
"      Perlman JM, Risser RC, Gee JB. Pregnancy-induced hypertension and reduced intraventricular hemorrhage in preterm infants. Pediatr Neurol 1997; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/29\">",
"      Effect of antenatal steroids for fetal maturation on perinatal outcomes. NIH Consensus Statement 1994; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Antenatal corticosteroid therapy for fetal maturation. ACOG Committee Opinion No. 210, American College of Obstetricians and Gynecologists, Washington DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/31\">",
"      Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; :CD004454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/32\">",
"      Barrilleaux PS, Martin JN Jr, Klauser CK, et al. Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. Obstet Gynecol 2005; 105:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/33\">",
"      Fonseca JE, M&eacute;ndez F, Cata&ntilde;o C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193:1591.",
"     </a>",
"    </li>",
"    <li>",
"     Working group report on high blood pressure in pregnancy. National Instititutes of Health, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/35\">",
"      Ganzevoort W, Rep A, de Vries JI, et al. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006; 195:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/36\">",
"      Coppage KH, Polzin WJ. Severe preeclampsia and delivery outcomes: is immediate cesarean delivery beneficial? Am J Obstet Gynecol 2002; 186:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/37\">",
"      Nassar AH, Adra AM, Chakhtoura N, et al. Severe preeclampsia remote from term: labor induction or elective cesarean delivery? Am J Obstet Gynecol 1998; 179:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/38\">",
"      Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol 1999; 93:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/39\">",
"      Alanis MC, Robinson CJ, Hulsey TC, et al. Early-onset severe preeclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am J Obstet Gynecol 2008; 199:262.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/40\">",
"      Blackwell SC, Redman ME, Tomlinson M, et al. Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? J Matern Fetal Med 2001; 10:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32808/abstract/41\">",
"      Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6791 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32808=[""].join("\n");
var outline_f32_2_32808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2262698\">",
"      OUTCOME OF PREGNANCIES COMPLICATED BY SEVERE PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2262705\">",
"      Onset at less than 24.0 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2262712\">",
"      Randomized trials involving pregnancies &ge;28 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2262719\">",
"      Systematic review of studies of pregnancies &lt;34 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13443830\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2262726\">",
"      GESTATIONAL AGE BASED APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2263105\">",
"      CANDIDATES FOR EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2263112\">",
"      Transient laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2263119\">",
"      Severe preeclampsia based solely on proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2263126\">",
"      Severe preeclampsia based solely on fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2263133\">",
"      Severe preeclampsia based solely on blood pressure criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2263344\">",
"      CONTRAINDICATIONS TO EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL MANAGEMENT OF WOMEN WITH SEVERE PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPONENTS OF EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/60/43979\" title=\"table 2\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/31/30204\" title=\"table 3\">",
"      Complications in preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27672?source=related_link\">",
"      Limit of viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_2_32809="Linear IgA bullous dermatosis on extremity";
var content_f32_2_32809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51248%7EDERM%2F56434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51248%7EDERM%2F56434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzXp0Ax7UcHnvTeKB1HrXunISBvYfjS5yKYtOPT3oELTt3amAml+lMQpIyRS9OPzpnJ+U9Kdk5HepQxQOTR3pMjPSjPPNO4DxwAKUHPWmLTvamIkzg9e3NKTwc0wHk80Hpjg0XAcD044pQwJ69aT6UL39KYEnU47U4D/61RA9cU4NxweRxTES0uai3ZYeven5568UAPHWlz16YqMEE57UvamBISevbvRn8abngd/aj6dKAHjvQDnimAnmnHoMGgB2eSego4x6ntTCeQDSgj6UALjOM0Z//AFmk74JxRnnnpQAHkAnFB7c0jEcetA5oAUHPFIR09qTPTpRuJ/CgBw4HSjOce9JjvmkHHU5oAUkZwKRi2MA8+uM0HrQOBQAvAxz/APWoGPr+NNIAx8x49O9Lk0AHHvSA88daUjPA5FIeBkDkUALz68nrR0xxzQfvHHrSE5oAUdO9H4YpOvOelKPfpQAhzk0np9adnnnApucfjQAHGaXsKaD7dKM/h7UAKD160UA5oJ6AUAGcUg6YooBGelABg9aUjGKTNFACnp0pOg5ozSZwMCgAPXgY7mk6Fh604kEcDigGgBF6npSe/t2p3AHTmm9OlABnjn8zRRnI9TRSEZZ//VSjGTnpUf404DNZmg7ORjinDruI5+tR9+lKODxQBIOfxpwPNRg8inZ/E0wHik47DrSZx9KC1AC5+bFLnHbFNzQM59KAHA07d09KYByacMY4/GgQ8EDilHWmLg07d6UIB2cEEdaM5NNzmlzg0wsPJJ4z9KAT3pnYAflS/XpQIeDzTwecVET0IpwPTsaYEgPvxS5AHHQUzPPIo3flQIeG55NOJz3zUYxzzR7ZxTQEmcfT1pVJPQ0zg9R+VG7pzz3FADy2P60Z96YSKXIGATz2FADxz3oP1zUeeetG4d6AHk9xSg8deaiJHpxRvxx0oAeWz2ozxx+NR7uKUMOuKAJN3FIpxTM8YJ6dKXIoAfu9etJnrTNx55yKXoc0AOzxS5FR7ielAYGgB5NGTjtjFMNGfU0XAeefzzQfXPFNJyp54Jo3AjrQIcKOoxTSfajPtRcBx5FJ9aaTjpzSbvegY4ijIxnNR59cUoPWi4D+nSgcZyc0wk49xRnke3SgB2MEj/JoB6Gm5yM96CctQA/NBb8aYM89KMnuKAH4wcg0A5Oc03JzzigYHvQAue/T6fzoJx160hGM57UhNADgec4pDgDnFID70nUmmAucqcYoo/GikBjg56/pTwfSo93rSg5FYJlkhzjqaAfamUZ5FVcCQHmnBuelRg9cUobFAD849D6GlyD9KZnHSgN60ASE4H8qAcd+aaD370A+tMCTdn696CSDkcUznNLzQBIGpcjFR898U4Zx2oAep65NLnjimDinbqAFBx1xS/jTc5XtRnApiH9hzxTj0x3qMn0xQDgA0BYlzjrSKSBzjmmZOKXJoFYkLYHFG7PpUe705pep9qdwsP3HFLnjk/jTM59aMigLEgPU0A54NMzS570BYXPrQTk5ppOR70ZoCw4HHFJuwMDkDmkzx60Zx70BYUt3xwf0pN3JxTSeT9KM+vWgLDt3H065pSxPNRg/kfzNKD39KAsP3ds0BuM44zTQ2elIGzgdwaAsP3YA7etHPakyc9qTcSOoouA/II60ZHSmZx1NAPPFO4WJM/kKOg5NNBH40FuPei4WHZ96Q/Wm5GaM5FFwHE4GBSE803PApCelMQ/J+gpNwxxTc+tGT3GaVgHg/XihSMY70zPoKUZz2pgPBGPejgfWmgnPNIOKAH5/+vRnjGaaDkUClcB54xmkJ9OlJn1596D1ouAoPOcUZoz9MUZ4yelMA4pD7UuRjPb0pvJoAdjrRTCc0UAY4OR704HHFRA8DtS55rmLJfpnNAzjpTM//Woyc9KaYElKTxUXXj1p2fWjmAlznvRmo91OzxmquA4HtTgajz9KXcaLgOyc05CM96YKOKLgSg+v1oB/+tTM5pAeaYEufWnBhn1qLOT9KcG5p3Afk9iKUGmFjmlyPr70XAdkU4N9aj4xgGgN0HegCQH1pRyTjrUfAPvRnBFAEoPNGeaZmjcPWgCQMcdaN351HkfrRmmBIM0FjimBuOtGfekA+gMO2c1GD+NLuouIfvz1oz7GmZozTAcSOOuKM4PQ5pm7FAbHXkUDJAf1pu71puaQnn60gJN3YdKQNzz9aaGxxRkZ65NAh2eD6ilB44qPPFLnvzQA/OOv6UA+9R7jS5zii4Em/PTrjNG4jr0qMkHODzQGGSSRTAkDep5oJqLdS5wPagB4OBS55qPr0PHvSg8HJ60XAeD2PWlyMVHn8aCeOtO4Em7vQOvHWmA+1KG/WlcB+71ozim7uOOtBJ4pgP7Ug4PGaQH3xSA980XEPzx70ZpoPGOOaXGfpQAucigcCm5Pr+OKQmncB5PUCjOO/FIDnNJnPFAClhRTe+KKBGIGyfagHk5NRBuRnr6U7dk57VyqSeqNXFrRkpbGadu/lUIPbj8Kdu9emaokkz7UoPWmZ9vyoBHc5oAkBAOPzNLnio80u7HU0XAkzt7Zpai3dPSlycdaLgS7uKN2TUIbmnA0XAlU+tLk1Fn1NAanzATbvwozUYbijdincCXPoKUN+dRBqVWzRcCUHIpQelRBuOtLu464ppgS5+b2oJ9qhzQW5607gTbh9KN2B04qLPI5pwJHQj60XAfmjdUZPPWjcKLgShvXNLuqHd70oPPWi4Eu72o3Goi1AbmgCUH6Ubs1ETxyaRmyeuTjvQBLuyfakzxx0qPPajPtQBKWzSbjgYqMnHU80bvei4EhPek3UzPr19abnB4NFwJc9+TS7iD3qIHr70ucd6LgS7qUHk8VDuHrijd6HNFwJd3SgNj196h3ZPvS7sd6aYEuTjpQrZzURJOMfjRuOc4xmgCbd26UA8+tR5JozQBKSe1Gcjio9wPSjPOOh9KAJt1Gfaow1BbGcUASE5HTmgHv0PrUYOacvcHvTEPViOmKUdeMUzPPFCnk4oAkzilzxx071HnjrRuwAPWmBJnnrxSZwaT8aKBDlz3ozjNNJNHXr2oAcDmimiii4GQYS+C2AwGelQLA0QPTcSSSOn5VsFFI+UHJ7VCUHZcHOCO1fOwqyjsexOmnuZeNoJbgdvrTg3QE1baIH8artbleh+Ue/Wu2ni0/iOWeH/lGhs+5pc1GQyqCVJHTihXDH5SD9K6o1Iy2ZzuLW5KGP9aUsRjJqINjnigMMA+vPNWQS5Jbg9fU0pY9hUQII4780uecmgLEgb86cp59KjFJuJBFAE2SOlGe/Sot3rTlb36UASBvXpQT6VEzcnpijIwDzTAmJOaXPGO5qIMTml3cigCXOOKM8Z7VHuGaN3ORQIk3cZpN1NBH50hx65HegLEm7kU4k+1Q49+acDxRcCXdRupmfQUjHjNFwHgnvSknHf8AGox0pM54yadwJQeeaN2KjJA/pRkdKVwJMkZoBxk96YD2NBIPJzRcB+eeTQWwcio85UGk3DNFwJc/SjOPrUQbnpSbwPei4E27FN3c0wMO/WkJB780XAlLUbqizigHvyTRcCUNS/jUO4cdaXcO9FwJQ3NGfc1Fu5HNAbOfenzASk0A1Fu7UZ9KVwJc857inZ71CDil3dKdwJQc/wD16cD1qENzTxTugJAfSgmmUnBPWndAS5p2eKiHHNOVhmmA/OTTw3tTOAfagtTAeecDFKCcdBTAe4p2Mn8aAHDp1pc85H603PfjFKvoetMQpIz7mjuaTjqetFFwHA8cCim59T/9aikMe4KuPlG3HB7VG8ZHXOO/NXmTCtncAeeB1FRyA8fdPGDmvmL9j6CUSntCqMA8+tMMZLEZAOeOe1Wim7OCcqOPr6Go2QhWJJVgcYppsz5blOWLccjJI7Yxmq89rlt3Tvx7VoAEnp+mDSlc5IAz0OBxj/GrjNrYzlDm3Mh4WXHcn3qAsVxuGBW20eecDnuarPbAEABQM8g54+ldMMVKO+pzzw6M0OCCTx69qcW7ZHtVh7RGPzYU8jOKie0aNflGATjA711RxUXuYSoSQ1SMZFA61CWMeAykY657VIrrjI6dcVupqWzMZRa3RLu7dDQG5PSog2WOT2/KnBgeSMZqibEmcHijdmmbh06Gk3e9MLEu7Ax6UuRjn8KjJ7UgPrQBLuoB9entUecZFLnke9AEhJ7EGgk44qNj2/LFL9KAH5JI6UoOB/nFMVvWkLYIoAk3D1p2T+dQ5zgj1pw5zRcB+epzzShsdelR9DzSZzyP0ouBKT3HAoznrUeTSbufbrRcCTPGfxoDZ/wqMnsfSk3dB69KLgSlueCKQt3FRAnPPSnKc4/WgBxODyc0bs96ZnPJFJk9e1AD91Lu/Oo8/kKN2RzmgCTcevajcRn9DUe4Z449qQe2aAJA2TS7j6ioQeKf9OaBDwxBz+Zo3Zxj9aYTx0603OOP0oAl3EY7Zp2eaizn8aASO9FxkwPy54oUg/WoweAeKcGIwP1oESknPUUob86YMZHpS9D7UASA8U7PFRjg4Ipx4HFUA8GndPSo+lOBqkwJAc80fnTM08fhTAUdadnjFMB5pxOKYDhn2+tL3yKTPPA5pc84559aAFzwfXtS56U2jPamA7HWim9aKANgnDN2XOMAZ5qExrgbdoYHjI6CrAGRheAQecUFCCc4XacZ9a+STsfTuJVdQwG75f7pHQVHszkY5xxj61cePcylcZHb0+tM8rJBGcnr/n1qrkcpUEWc8MeMkDt70BOMYyO2BUrR4yOQR6UYyRjHp8tVfsRYiMYx09se9QvCQwHbPH0q15YGNhAOc0p9ePl5PHSi7E4plE24wSckDoCemKjZShYYPPYjvV0DLDkE9DSOg24ORj9afMS4Ge0SkLkZXIGMVWksYyOUUc4Jz8341qkqB8wPB54waZ5YBO3gd8jqM1cajjszKVJMw5LWQEnjIPp2/CmNDKp+YH5ulbbRkxnaDu+8T688ZFV7mMbeQeTwT0//AF10wxU0YSw8WY7sP4hx37d6PNDdGGM9KneEZIYFWzwSc4pJIcljjDDuOtaLFvsZPDIZvyB5eXwMnHGKN+SoYhcjPXOKT7Mm0Z2kdz6e9IIFPQdPQVf1vyF9XH7sDBOcccdaBIORuG4dRmojbA8qBkfT86PII5K8DpxT+t+Qvq5NuAA56/rS7sZyMY9TUHlLgDJbJwAB3p/2bgA7iOxNNYtdUJ4d9yUN70A56Hn1xTGgfDct05HakEcqjG7Oe+On0qlioCeHkSbskflTgeah2zcYxjPNGJNg+Q57HNWq9N9SHRmuhICOFx7/AFpSfXioiT0+bFIG+bBOBnirU4vqS4Nbk2Rgn0poPWmBt3SkOT1/SrRJKzZGKQnp6g5qPdzj0oyBmgZIG96UMAOeTUO7mkU0bisS596Xdx1qLd3/AJ0m4mgCXPGM0mQeKj3evT6Umefb1oAlY5PHX1pN3oaYW7DvSBj2xj1oQE2fy70Kcj6VCWJ680oP5DigCUkbaTPrUe/ilJHT+VAEobkHrShhjjqOtQluAR1+tKrHHuKYrEoPIJHNSA9iar5/yaepPH1oAsKeBUgPA5+lVg3TjrTw1AiYn3pQ3FRBuflxmnA4X3oAlzyeKcDxUYb8jTgQBx3pgSCnCmZ460ZqrgSUvXimA8daUdqaYEmeQenrS7vxpmcnmj04GPXvVAP74xzSj1poPPFKD34ouAuaKF9Rmii4GnBcMZtygBeQd2ST+HQCrcjZU84PY1I1u0k4MuH2cbtm0n3I9akKKDjAIHI4/pXyTavofWOLRURdgDZDHPrTmXGeABnPH+ealKEkF84zgYpCD8wOQR2pEWKciYVhESX7Nnp9aYkPz7hnP5c/WrWdu1geSc4A70rKzE/LuHTpV3IcSoQx5wPXk0Ip8sFckdMjv/8AXqVlGO3Pf0phXZvfqR07U7kuJGxyenDdSaAq4z8rHHORzzSIUz8wOCO1SIODtU89D7fWmIrn7/zYA6Eno1M+VDhzwR1A61LI+1uny5wSB79TSLETGxJG4Ln/AHR7e1IkPLBClW4bjPpVCXOW4GF5C+ufQVdkGyJV3gKSSSc8Gqkg2MepIw3Iq0ZSRVwhVF43EnP0HqaheLLLggHHIOSM1KyYXJRSMcfUmn/dODjONvNMixW8v5QSM/h0J/rQI+CBk5Pc1Oke4bQRgjr0HehEJ5OQT1NO4WI1iBbLAZ9aGVFxgA808ocHBGeuPX/IpUOCN3b9PrQFiPyeMkZOcYH9aXy1A5OPf0q0icEAfr0pdoYkMwPqeo+tHMPlKgUEjjOenahYQOV9BkDjNWwi44+71HFOHyjkN+NHMHIUREwyHwF77qPLABKhiP8AZGeavqrNnsvQ570ixD2yTjHSmpByFMRKwyf1H+cVH5a7SBj24rSMQLYOAQe/ao3txIuNmeO2aamLkM42wZuAMeuPyqJrbjuSfXNaghCoMZHTFPESFPmAB7nt+VWq0lsyZUkzCML5JXJGe4oaN9vbn0OK3GgDMcD8SKY1uvJwwHrjvW8cVNeZjLDpmEc45Bz6Y5pvrWw9sMHcMgnOWHSq0lkCSQpAIzx3reOLi9zJ4drYo59e/SkLAYqy1o3IRuB6iojbSk4GMjnFaqvB9TJ0pLoRbuODzRk9TQ0bgElW2g4PHSmFsjr+laKSexLjbceTgcGk3cgE4x1pmecUnYUXCxJkZOcijd83WmZIpQev9aaYWH7qNx5qMn5hSgk0CaJacPvYzUYJ9RTvryadxEmcZzyDSg9vWmDJHbrTge3fpTESZz1POakGABz9KhWnhunYUCJcnHXg09On9KiGM9aeuBQBID6U/J4BqIHvT1Oc4oAfnmniox1OetOA6GmIkXpS5plKM45qkA7n8KUHgU2jJ6VQEg9aUnB7Ypq5YgAckgAVqahp1tp2qw2d5ekqoAunjjz5THqAP4scUr2CxnujxttkR0bGdrAg47daKu69BcW2pvHdXJumCIUnJz5kZHyn8qKa1A6ZkfYHRj75HNQToHwP4hx/vVeIBBLdH44HWq8sHzHHLEluD+lfIn2MkU8oY+CBgcg/zpQuVYgkE9iensakZMlV4Of4lP8AOh+uG6A449+1BBWKgsHUDOc8+tGCBhmHHORxz6VMFU/MOOcYz29aYkTYJBIDZ5700Q0V5RuXOACRwB6VEc5UDIzzg/z/APr1YZCrFcjjABB4NI+ACGHzdvrTIaKjqA+7Gc84x+lRZfeSM7QMgDufT2xVtowOW4Dce5FQOoBAT7ucg+lUmQ4kLEEjbwAOQf1qYZyMDMi44I4I/rSMpBbcOME5A/SovOwMqA3y5Zc9KogS5YpxzyARwOh9qpSOPmO4EZxjv9PpU0mVwWJKdie1QsuWOMmTcD0A+oNO5mxjyDr0BYjOe/8A9amxZKl8HBOcnjP4fhTjyhRT8mdykDv0/wAimLxuUbuuT6jFMkfs25AC4AHvQVAO4nBP8qkVVKgjoQTmnIm3GTn8M/jSHYhVMJwOv6UqIo5wGBOcVMoJzzz0+tBi+Yckc/55ouPlI40bjJORk+maX5T0Jzz+GKlKn5v7oFNEe7t27UBZjADgHHB9e9PUfNlufp/KpVjC/ePansmzoc5Pp+VFx2I8gBiRgd+M/QU1svkKrKuOGIqzFGxIJ+YZxzyBUpiXHBGDzjOaLlcpAACPn+8Opo2D7uD6ZHanCMrIQ54I6U9Uwd3Xvg07hYhMYC7QSe/rigxhumM+oqbAUew96UFVBOOo5OOaLhYqxwTGZgSGUdGz0+tSSRsDtDNj1J4qZTjIxlTxnB/yKFU4OTwe46U+YXIVDBlgTkew4Bo8jJGG/wCAnrj8KsiPA3BsqTjg9qCgGemBRcTgZ72/OQDkfrUbwgHkZB65q+4AHzd/Xn8KhCh1xnIBxkCmmQ4IpNCpJKgbumQahks0cAlQPfua1REvXbg9QcdKjaEqx457dMVaqNbMh0jClsVAyCw7/Sqz2ki91Ocd66R4Sfu4PGMY61H5JbJ4wO9bRxEl1MpUEzmnidc7kOB7ZxTCRtzkA56V0ckIAA564qB7dG4dRjPH+NbLFrqYvDtbGGOME9P507OBkZrRexjbHlrjPTBqBrEhhhq2jiIPqZujJFYEZGRxTuw709rZ16beOvOKTy3HBAGB+daKpF9TNwa3FHQetOyMfjUQI4HTnvTgx79Pzq7oizJgfWnrUQ7cf/Xp/bmqFYlHPXNO79+lMUmnK2M0XESDoacOBnP4UzIHTigE4PGaAJB7ingndUYOOMGnggmmA9e1ODY6imZpc/iaYh9FICMDHNKaq4CjgAgkHrmu3FlPqYjvb/wvczXLqC0kdwIlm44ZlPIz7VxAO10xjIIPPT8a6zXLS11LU5bxPEVgolwxjaR/kOACo46elTIqJj+InvH1eY6jALe42qBCvSNMfKo9sUVUv4BbXTxR3UV0oAPmxElTkdOeeKKtbEs76XPKDkdRjsaqsPuqRz6Z61cmAy2CSuM5J4pjxLsBUksSTjHU45r5E+0epWePAXPBx2HQUgiLRsQp4PU1PHtUDzHVMd1GBTmy+CqsevJH+c0hcqKLDbKVP3eowKaygFg7DLEjLDgfSrOxn4AwOvy1HOBvDgHB6nP9KaJaRTCFTt+UAHA/xqKVSpB7YG3Iq6UVlfA5Bzg9R700ws2VKknnBB6UzOUTOl+VVHQjgfSq7K8k3Ug9Dn6VeliyQuTz2PfvUU0RHzKDk5pkOJGSFWLouPlP171UuYyjjPr+lXiCU2EjIIPXr1qtOgkQBm24Ax8vSrTuZyiU1UsrB8YJ6/z/AKVGOWK/x8457mrbxnAYHP8AT6+1RSxEYwOrde4z7VSMnEqRrmNdx2kA7eeMjpUyRAYbHHXp3qYxgrgdQcgjpzxipEU7zzlmGBj9aLiUSONQF3AYB5HNO8rngYHTIqwqAkYOSex6+lTJH12sNuOg9aTZagUGUhxg/wD6qVouehXPQmrqQgnGMA8e9KU/55KBikmPkKaoFAyMnHpzTghJ5xzzz2NPhR3Lh1KgdBnqPWrAhZdzHaFHzZx3+lNuw1G5XWAr8zDk9Sec1Mq5UqBhu5wDVmON8rkFvU9eKkW2YcvuJP3So5NTzFqBV8na/Dd+e1OaEAEZz36VN5GGJAyBz6n6Uvl53kEjPTNHMNwKhtldwWJwOw/wpfJO0sC3p0q0IioABXjrtqIggvk4x90dfxpp3FykEKkq+SGJ6Y9PeiUrHlVXr17Gq8iSSTsIzsLHg9M1VmM0ETqEZyOQT/I1olczk3HVof8AbFWYoWZecZIqRbtGKgsdpP3vQ49Pesry5ZAzMhiyMne2QPx7c0+EGKMqzBh3O7kfQd605Dn9q7m7EvmDeAAOOOBTlRBgrg+wFUbDLWu52EgzjHf8vWtFGOwBoSoPr3rJqx0x95XKlzAJVZGySw6g4NRwQOWMzAhCoVfk+8R1Oa0THzh1yeff8qkS3jW3AWVt7NwhHyoPb3pKXQpU09WZoiIA46nk54/KmMjMWGzdz2FX2gy/KgkdD2NUzK63Yt5E2kruViOCPr2NNaktJEQiDsozjPXH9KUw7lJBGR+n4VYjgZCATgHtmpBDjhQc/p+FLmsLkuZawbAAoHGeOtIYgeCuD09q0TGE+8rDJ78596GhJPCn6jvT5iHTMxYFUkjvyeCTUcltgZK8H24NajRPu4JJ7jpULRbVPXPYe1NSJdMy2hA+4Ax6Y71EbfjhDnGcjitdogobghuOc5pjAqCGB98jtT5yXTMWS37YBzj61G8C4ygyPcVspETjGOvHHWmmHGQcjPUA5qlVaIdFGD5LbtnTB4p5tyDkFjjue5rYeFeSFX34wKYYeAqAn0HFafWJdyHQXYyHR07D/Gg7l6YIzj8a1xb8Hgg9+Rn/AOtUbWoH8Iwe1WsXNdSXhomWZSGOYycYxz1p3nkEAowJ6e9aX2ZNv+qU87QfSm/ZBk/LjAxjrVfXZIj6rEpCcZ5DU4XEYJ65+nNWDbg846dBxSNAGzkDB5xjmqWNkS8IiEXUeT1J9lNPW4iI3eYo5xg8UPaAAKB0OScc0htQJMEZAqljX2J+qIlWaLA+dPxIqWMiRHdCrKpwzA9KptZbjkYIzjIAzUYs234KfKO+MVf13yF9U8zoNL1D+zmkJsrW68zA/wBITcF+laP/AAka9P7E0f8A78n/ABrkDAysNjsq+gNA+0KPlmOfRsE1axlN7ol4aa2Nq/uReXTTi3ht9wA8uBdqjAxwPeis7UNsCKbDUvtTYG5Xttg5HODnnB47UVqsXTRn9XkerdyWPy9sDNSGMbAyk/n0qLkk7mz/AAY9DThKsbfOVGQASx5H0FfNH19hktvsZnMm7fjCEDCewx2PWonYkjJYDj7oPPJ7Gp5TuiOwbcdwcE/SmwIwIyDu6A9c/wCeaAtYquP3hVGHBxxj/PameWrSDbubHG3GPetGK1+UgAAqT19P8ab5RxlmPeMEZJH4n8aZNjOMXyHdjIJORTZF2AYbGT+IBq4yBiz5bYB+YFNKZPsT0AoJcTMMSrx83rx/npUEiOWYknjn8a0biNwM7BjHPGarSLhgBwBz7++KL2JcTPZc8gcH7x4ycegqMK21yuGywPPXHUf4Vd8tg/HXqu7t2qDBZtq4+UdT2H1qkzNxKzJszkkD0+nt6UkcbFio5C4OcfxVPPGScuODlQf8+9SBPLnG4dFyR6Af/XxTuQ4FIxj5vvEHAJz2x3qWKMn73Azj6+1WFhYBQAckc9OD6GnrCygbxgjhQR1Pp+vWm2CgRpF842nAPY9+PWp1QhFxjB5zVhIzksCQV45PH/16ULghSBnqTmpZoolNEAYDBJJ5GM1Kse4HcCWPSrSRgDLdTgAimMQDhMcn8v8A61CK5SpIirgfLu65oR03bCGDemepqw8BHOPkPt1NU3tmZtpUsCcjn39qZPKXY4+4AB/Q08r8vBY9Rx/M0qnyw4wW4ycUIQxZVIBxnBPSgvlIViUk7W3EcD3/APrU0xuZGVshTxluDVvaxJB3c98YxxQyMHG3GDjOBRcOWxCYlRgyBwOenIA9qS6ZAoKuwx0zzVpYzj98pDEnt0Ao+zqZAxi7EDjJoQ1EoTXLRRZAQjGM4BI/z61mXsF1JEsqwFg33SM8nrz+Wa2p4wDkL83YEYP+fesu/a7tE8uKYxFcMXGSXBPQD8Otbxsc9ZNpow5PMJI2xLk5YtyW+p7CkSORRvwM4DLxwPxqwUkndWHDMSdoXBJ71Pbee03ls5EbHDHH6Vrzq1zgUHexca2kuLFRbxsGYcN0PPoT1pdJt7uCB47reNpwN3HFblooiiVPvDBAyOn0qlcxys7RR7VbGRu5A9gRWHNc9JU7IlSEmIMxYKM844/CmOMHIQEnrjqaLRJljYYLHGemcVIwbbtC7io+YE5/Gs3dFIrS/c3TJlQQR8vINQtEhZZJFzHyCMkY961I7bKEgYDcDPH1FNEQwQcbvTt9aSbQuVMowxZXJz8uVUg/54p6qSABkgZOP7ufSrUcW12UgYB7n2pMFmcDBYeuAKG7hylN4FbgAgdwO1QCJQAHcsenXBq/cocDBAJHc81W+5u3FSynAJGc0XJ5SLad3JA3eg5NOQA/KWBwOOOT/wDXpk1yoIAVvLHXHUCiDbKxMeJFJ5zx/k02TYjki+YYxnHU8H6UxoBxgMM8/QetXtg+6AAcZweKeYlChEZxk9+ooTDlTMryFwcdSc55ANIYODtTtnjrmtMoASjYBHI4xketV3Qr80g2gjgnvT5hOBTELEnPze1J5CuhPYe2KsxSq0xznI5U9Pwq55A+8EIDDrnqPepvYFC5ltDlBgZHoMVGIVxgDOMZxxWwbYAErk4xjPFKkG07hsJxzmncPZmMsBAxxk5O71pDB2ODx0rZNqWj+7ggZH/6qY8OeuN3bApcwezMkwAqAAMDr6CjyD0Axj06Yq5uUttOMg/cx39xT8KYwc/h6fX0p8wchm/ZizH+HPp3FBsyF+XDDHOBwK1YlVtwdtxPcYOBRJFuTaVAPQ5BwKd0T7O5kCyxuxjPqDjFH2Yk7QMg9+gFaPlAZ64zgKT0qWEtG4kGFfpn/PejmH7K5im03gEuEXIBPoK7WfSodKk1G8ttLi/ciO1sEkTes7tyZOfvHFc35BlYcYDMFOeMn6enHWun1GwtLOxmUTXkt1ps0SvIZcAbuWEa9uO9WmZSp62OR8X2ENtrzxW6R2+5EeRB0icqCyj0we1FXdf01bXU3jid5IpFWaN5PvEOMjPvzRRzEqkzr2c/MF3rjt7f41nSRl5kJKkK3zgkg4xwRWqFZctk8cHHJIPb61HiJwWO4EddozxXNF23PYtcciuIcjnnoR+tCpkAY+b7oJ6df51Z/eCMDcAnfv8AjimKAVK/N15yOP8AP0ouFxzjGEUMijbkNjpnP9KNjZZ1UkDGSPXP+FKoU55xnpu9/b2qWXfGpWUHgk7D296BFTyyqsoLbST1OcCkkXeoxjcM/jmrrMHY4wefT+R9KYqNkFcdcdOtILGe0O5d68gAnrVSSDCYMRGeOeeevP6VtOpVWLHk4GT0H4VRljLqoz0J5HPHp+lNCsZnkMXG5AxJAAxjPFQvGpmO1QCeoHHHpWtPGPPTnJ3Y29O2P50y7t2QlyoKgYOOM54B/OgTijIuIXdCpOWPAx3qVIVl3btoIbaADwx64H5Valty6DymMbkZ6ZxjnirBgXsioqgMB6cdc+lUiGtTNgjRghUbW2j8+eKdMgUYBHzH5W/LPNaMEIWMDncp4H9045pJIwyjbk8lgRzTuS4lVQojAJ+cLnJ7gf5FJ5Q8zrhSOR3/ABqVYgrZIwMfmO9MZcgFBwR1zyaVxpD2Up8q4I7/AFqBHwM7AWPXPAFWzHgtwMAc5PH4VBs5ULncRzgc0XG0QfeODyOp3ccetSSHzDwOMcbeM/jVgxrgFRls88ZzUqw8fe5yOc9aLgolWOKRoSEXg+vb6U2C08s4wB1JyAPzPf6VoRxeWAC+1R6U0R7XOwNknIcjOfWi40iOOMR/dDODx0p5jzGDubdzgAc//WpWLKSmWV1OO+KdCqSSKSGzjPWgdivECMh1c8fxdc/T0qdUySGGcHg7v8irESKJ2Ax/tHHOfU+1OaHBG5ADjgjmmC0KjQLncNuOegzgd8VUktBK21id27527/lWjLtiYBgNxBO7PAFZltKFnj8wqyuxUjdzn6dqpNibXUpXun+fMBv2qOMKM021sYbdgGfzH5ChR/P/AAreaFGZwGIGMDjO4/XtVGRIftKlyTjqegBPcVXM27GXLFa2KouAW2LkEHaMdD7VXjimupCYm2lfm3gY6dBT74ukxjSMgBePlx16EU+y+06fIskyo0TnJXJ/I+lNRsxfFuEcsg/dfMvbk9T61Olu23LNuBwcd+PekYeddb0yFbAC5yBz64q+q7QqkZPsKmW5cUV402Lw3PUex/xqERSbm2YOeMsMEVfGWKu68xnAGcYppG1jjO769qgbRWjVyg3gt2zjrTgnzgYOe/tVsIdhO0YPQZ4prRqNyktjqM0AU7qNMKTyQck4zioPLwCueScgAda0fJGV2uAOD7/X6VXHEmH4ABx6fWgV1sZQL27OBFFIGUgCQdPcVJZxmGMBkxnkEjAOauSRqzbif6//AK6Uhedq5GO46/4U3JtEcqTKMzo86jJ5OA/THrVy3UhQd25umDzxVaeElgFDjbyTmrcAJG5FBOeM8GkwUbCPD98rwCCWBH8qoT/vN6xnJjXJJ7jpz75Na8r74js57dM49RWYunbblpIdgln4Z2Jwee4HTFXTV2RNNGSJJTLFDKqibcCAe+ehz6c/hWzZM0qsrLtdSVIGOMcEe/1pY42hkLSeUHQuE3RMCfp2A5zg806C2KBVVcMoHzeoqqiS9SaTeo6dYxKvB24wM9acvzIMt93nnFEjFGJLjoecdTVZL0RsVblsjPHFYm6lYtZBYYULj1PWhUBUkgkHkev19qZEysMsqgc456+1S+aPLKtjDAge9A7oz5oAlwGjBGeSW+b8KjMYVWdgCM5PoDVt1U4c5wOgHXH+FV7oFlIY/KPmGOeBVq7JdihPH5ISXe+5gSFOMAf7R/vZ7VoWIS4hEjOyscbuKp/ZiSsjuABluOrHP86s2MqlHRl2kHIXPRf8960nGyvYxpy15WTzRRjaHGGYZP0qHaATkbs+3Qe9TSgnkdGGD/jTsLyVOD785/8Ar1ib6Mg2OoMeWwzg4PFdkbXUHikW70S2u5ZtjO7XAQylfulhnn8OtcxImDlgCFOSp5z7Zrb1CKz1C5e9TVba3jbaQkxKvDgYwAOuMcYqkyJxRja/pmqC4kv9Tt8GQ7MoQVXjAXjpgdqK09R1C3e11aeGVpBciKKOPHzOUxmU9hmilLyFFXWpemjZU2hVYY78c1UtCJLhRwGB6YxWhkb9rOwAHVRk/X86ihjCXBfnAOcHnFY6nckXJQuN7AjH3sUjQBispAGBwCuO/Sle4R12hRgjDY7UglGVVEAYfxEZB+lArEQQs4f5N20YbPf29KgW7Mbqp2k4xuxk+1XJWk2DcqgrnPqD+FVrdZiSskcQV+AXGT+XrTXmNItoAUVQvAyRg8nn0pohZWdcgEc5z681KiJH0HzAEc/XpTZ5AzEdlxwB6H+VAhjRKcIVducZPSiSJI1w+AxGfunjJ/rUm4s5GF3YOCT6jFOaIF3RizgbRgDoM5/pTBmbcxJHKrsoGW556YNOuFZotuFG7GcnkfU1NNEY41LDKswYnHIH/wBepr2BZLY4ABCjj+8KZLM6IMHDjBYkkZ7dqY8bs8oGCoiAGfTNW4YfMhUlWZmfgke9IoMkroVYqVVSP5cetFxWuVpIgBubOAzEZpkrB2UKGwpHHTPFTswIy/UqScDv3ppwrbmO6Mjgg8EemaA5SqQdq/KQW6gZxz60AKAyBSATnPvVgqGkKxq2cblHpTSjBwmR0OMnBzQFiGOLD8MDzyKaUCvyCT1yRgn0qxGdzscHHbFQXUqmVACMjt1oQWZJ5W7acEjOMdh9akRo1JJGRjoOOfpTYS0sZDtkkZwOCfxqTyCzHbksDznkD1pj8hoBfjgu3I7EU2MuWJ6d8Z65qZYmUnONx7eop8eVlIJI7qCOPr7Uh2sRDa58shsnGcdvr+VWLeNV6gjsT1x7CkEW12lV8Z4JGatR7Dyd7SfwgH5R+FGoWIlwDle/UgE96SQBFxErZx948ipHJTPmKJCQcbeMH6UyTPyuHYq+eh4B+lNXJsZN25wGZVdm4IPc1mx2YFzzMsZJGB15+nbFbk1udi4ZyQc7yvf2FMSAT3R8yExHZtIPU+p9quL0IlDmC2ZeYsbtgzn19ar30ckiOLchHIwdv8Q9K1mj2Jk4bjAbG3d7Y70lpBHMThMAHBUnOfpU3G4I5qO3Z7hHuDkKMkE89KtXRhEaxWwOW/1gYcge3qK1LizMQ3cEZwARg/5FU59OMzxSGSVD90KEOJe+A3atFK9xxgiOwi8xDsA2j+FmxV6K3LLuO3cMkH0+lWIotsQYoAQAowO3+e9IuRvOASTxgdv8+lZsJR7FRomfO/GD0LH9aquuWUN09DyCPrWvNCQBuVlUjOc9Pas2UYBKtjHJz/SgnUeIwkfBIGMEEdB6U2VSp/i24BXPHHrV2URJuMY4IHzZ5NV2O99vBXA5/lxQTa5CMuSVPzdeR7UksYPVRs6gA8D1qysZILZbIP503ypFcBlwOoxzx9KRaiVfLyhwgU9h14rMuJXS4AjQKq4Y/wAXHStm4kSPajOWBPGPX2rM1NFW5jKjcSpBC5yefShCnCyJ4I45eVBDY5DL6e1SKu4KW4xkYHP+ealtvmIbbtIGOe5z2qZlADiQ85wAwyD/APXoYcpRj4XG8qTwWYcZoiUqSdyhgM4H9atsi/LgjJ6E1DLbFX9ARjg8nj19KaZLixlxO80ATcrR5U/dAAweOev40whADkg45/DvT/KXIzk9ycnH1ptyhOcYYjt3NDk3uJIryqWYFmUqenOcfWoIyqMQyOyEcAY69OfarW0vlSSR13Acg0NExQ5HPXBpKVgsQRDbBtIB5xkdsUKB1BGRn8KkMe3GFBx+lQrIpyuVZge+ePwp3FYigLI7F3DAHHTn8qduR2cScepGP1qvkpJwcgnPfmp5NzKGIGD0x1FF7CGOwmkLsEBIwTg8j/Gm3Qdk81CuQAoAGOAMdKkSL5AQRsPI96VkdQGPzDPYVTkyVArQ5ChJh8pweT29ferDNI0R2qCRjipjEFAyqqo9RS+WobKgnJyeeMdqi5pGNtBsaMrFLoqzEjkNkYNdldXT27arBb2FvizWN4FMAbfESNx98+orkTH5qjIK544GB/8AqrWlistI1pUa81Z7qBRGHjdQoGM4APO3mqiTVS0sUPFCltbn+YIWjRljA2hAVB2kD0oo1OGKe8lkgaUrLhmec5ct3ziipbHGLSOgQExN5bK8j8bgMZPbFRFDnBH1z0HvTRudBtJUbuTgcn19qmlbZHiNW6ZYkbh+IqGjquN8kRRj5izg5wT+eaVASuTuI7gHrTs71YSHC8HGMZ78UxJf3bIqnIPHrSKuWUiVsMxzk9On1o8tEboPlGVJ4FQSTM7bVUgLyc9P0q4rMrbsDZn06/59aljSI/lIJZMADO7vSeVJ1I3liOCei9/xqYSLkqg7EVEMtCVaQklDgegPf600x2F80bU8sBV3AMQOntSxSkoAwK4Jb0yM4BpVRYiU3fMACW6DOOKaTsXdnbu2qx9aq5NgYpIpIYhVOeR6Y6flRPMHtCcEZKsB/X8qoynCzLIxKebkc8elW4CqpKpw5jHyqepOOeKLktDR8kMKkYVsv9KbGdsrsF2h3C8tjFPuJEMgl8rG5RhA3AUDHJ9eaTcTgqv3XJxj0HegLFdoyRggnK4H4Hnj0qBVbd5bDYo42+mfbvVwFmVAwCsF6qOCCen4etNdHYF12sCcKR259aLjI4QVckDI6k5zx9akaJX52rwOh7/SgE5+RQQ3B+op8wUWwbjcTjjr+NFxNalC8KW8JZ3wCBlguOKy1kjLAsW818gKcEEdjmr+qoJ42VgHckYUc1hy20k1xBcRn541IjHbJ9a1ikRKo46I6KziAAIVi2O5Gat7XQr5Z2nBIGc/pWZo7yGNRcndKPlcnOAfb1rZiVmVh0VQcnpn8qmWjKV5K5VEiA52sHzhmx0/+vThh2GAQz9ec/hU6RKv3gGJ5+bpUL70kJQBiCCCDz/+qpLSuWINiKN+CpPIAwQaWJo2fdEwZlzgsxHA9qikkkkUsmPlxg/yGO1Z8M0rSu4jcoo6nn6n6VQlG5q3Uqx7SViJx94DP5+1EASUkqGBx85xXNz6xCD9nknRZGONvf8AP+lbmmmPC+TI4Uj5ixGS3cgenNPle4rIsTKjofmK7TnI5AHvVccKFLK5OD8pOT9TUdwQrFBn3wxxnPWq1xeQCSBZ508rPJKk59M45NG+hNrK5rOTKgYSBvfjkVHEuwsHJOccdfr9Kx7nUYoZtkUqPH13AHn2Wtq2lEkYJcFccHGAOOn1ptW0JTT2JrwxyxkoBvAHGOtZxe7NsXYubYOFJz8vrnHpWqHU4JQbiNzYP65pbe5ktoLmN4Ew/I4AUAjHTr+A61cbdQbfQqxRb0bbl8DLHtip7d1BGYxjtxxTrcKAil3ZyMPH0H5f4VO0kUEQymxyMAqeB7Vmwd0VLtTKQFIZR/s449Pesu9tpATjOVYEEj9K2Yjldu5ti9AR2p7Rl03ou4DoXPBHekkBzJ8zzGUZKZxv6gH/ABqVoIxCZmkbzVbBjwcjPStOZ/Lg8othFbJwuPeqUqQGRfMKsG+YhW5+prSNriempHZzyMyqB8i8EHjirgQuVZjnH+1j8KrtDaW+of6O5MTqCyufun+7WlM6sitjKsMEr2qJRcXYcZXKUtpE77yh80Kc5GSBVaSzjcxuwyyH5ccVtWgaSJiQxdcHdj8gf51UvC6RZkU4OcZ6igq99DPKBUOQo9NvA+tOX94CQfu8bQOtZ9zNcuWdVBiXjB5/OtvT4vPiVoSQSM/MMdulK1gsQYV/ur8obapwBg0ssDBCHQq/bjrWhDb/ALvZKiKFxh1bJJ9D6GpvLWWPKHYqA5yeSfx9qAsY6W67dxBB9SevpUJgLZwQCM49q2TAkyHnZEgzuPGKq3KKIg+MBvu54B/zikKyM1Ik3q3QNkYxwPek8o7gh/Men9avgLPLhSDtG7IXg06S2VTt534zhT+Q/rRYGkzLlhITcowx6A+lZgtd0s0zLhkG7AXIP49vpXR3MDIqKrDcp59BVV7Jmzj5TxvHr9BVRZDhc594HZlIRWY9yT8uKuRxIUHB4HXGaurBsdo8dDge+Klhswkm4DapPQ9D7UEuNissRxk53HjaKY0fyFUyHJ6Dt9a1YYwI1YAZbI5FQmAySdWZguf8KCkjKlQuN4PUYx6/jWbdyeUq4zuY8KeeK6J4gSFSM7SCQDjmqV3ZoYguwlyeq9W46U4K7Jkna5UtZsxDzSxB5OP4h/jiu01X7fDcbbXSIJrdUXyXeAuzLjjJPOf5VzmlWMFwxe6uDaxoAIwsZYN9fyreWG1RMnxBcKQP7j9/bNO1iXra5k3plluSbu1FtMVBeNU2hfcD9aKsTW4+2Bbed7sbV/ftn8jnn2orNo2SViV1lJKBlG7CkZxk9hT7csEcOxDkEMAPvVGkitKqz8ITwQCG/OpNzh+XVoUYkZ5zTJTZOFBQBRsCjaoPJOfT1qvKAXLAbgRjPbPrQZBHl0RSeh603EjLhQqDHyrg8d80rFKdtyVmjkBxjHXaRyD0/GpNzNBtVTgrjc2QfcVUibo0jAHjOP0qRmbc5VwwK5znqfWpcS1Md1JCEAkH5varJT90oVi6jGW/u+v4VUt9k2d7EbsD5atuCkY+clBkAZ6e1S0acxYVMfekyODx+I5qMxFj93LbmJAb2pInbDMSducE475461H5gyQuQSDyRgEk0mMhK7pGXJ3KeVA7UxYmMYC4USvnJPP+c1KgPmzt90E8g9sdqsII2iWUhtqYC5PLHNPYGQXEZlaGNwx4wAeNopHikRdzyks3y5PHXHIp0kpkkXDfdyCCKfcRIGUyMOvGeRx2FFxEDDG4MQAO3cgdKQtvIVhnDYO7uB6ipn2NHub53znIHK9MfpTPMI3AKBuIUEjr/wDXpp3ERsEQqXbPPGOO3alidSvzqCF4IWoriKVkIJwCclWP86W3jcjy4yQFxgd/oKYjMvZP38zoSvkplBnBLMccenc1kJGY5QZGEjSc4Bro9UtY5nVw53Ank8k+30rmdailjniVSI1d87geePXFbwaat1MKl4tzOhtvJzGbaQsRlZMKdp7/ACnvitOGZUiK7mG459Sa5rw/I7wvIQyOrsMdmI7+1WJrmON2YvI8pyAucDPYUpxuzaMoqKbOhedG+Ut8y98dKhW5UAq0fyk8HOcCstr6MwF4lOdhckjtjmoNI1M3is4O3BAZSAOO34VPIUpRuka5PkkiMMzNz/8ArqhPK0W5VGwH7ynsKttNv5XbnB+XHJ9aytVEzWbtG+CzqoJU5Jz0Bpxhdjm+VXKDxQys0rpCJeeecgjuT9O1buiXzXFiksW5UHy7XHQD+dYl3azRmLeMtwpIPVvXFbWjRMLVVUI+zlvMJUYPfPrW0lpY46Um5O4t7cSTBY7ZWEj8qijk+lU0tZo7dl1MR72BWRVzyB+oqa4Xypbl90kU+QIvLHGOh9z3xUFhFNmeSRjIGH35ATnt196IxikVUnK/kZVkkM188bDbg4RSTj6100c2bkwREDJUBWOD16k4wO9Zuj6GYbk3KsfKH3UJy6t3+oqaG7Juv3kYyrBN+B93NOfK9jPDt09ZHRwAo6h2ZWxnOSVPYYxTMzSXD+U4UKCeRzz/AJzRBewwhkByxw2MYA/H0qrPdwl0kR4we3esbeR0yeuhreWsZJVhuPJZjkY9aQeY8jCNQ2Bk7h+mKpG8A5cnPQbjjqOnvVm1IKq8KDeARu+9j3qbdwTuWoQHdVXGW6jOM+3pT5ivnYUExIAM4xg+1QxJtm2SnK5yQowBVxiMFlC+Zjk7u2e1IT0Mm5gAlWMqzOXGAOpz61U1Wxk0xneNQiNhBznJ6kj09Oa0riMyLkoQQMkL2qhcI5Ibf+8U5AB/n6d60hJLcmcXIyZIIborNFG8fkopcYOC2cH8+tdHaQs0BAQbgcDjr/8AWqjb26ruZ5CpY7yMHaD24rUtYyZlY7lU4B5/OicuZ6Ewi4qzGwo5dkEaxsy8HNZmoxM8X7xnZcE/L1J7H8+tdDc3K+SyptDqM8dKx7sl44yGPA4Ucn8/6Ul5lJswVmVITAxQSyJtUDqPX6mtfSU2QKpYltowMEmqB0yGe+inkVvMRTHhfugZ4z+BNdJbyIflTg42kAY4+tObTLWhCsO4gqP3zHgHuf6U54hucERtwuCD8wPfI7CrIzEMRlA3XJHvVKXzWuFYbQp64/iPvWYN3HKMtsCFV6n1qvqdr5cO7oOgx1X3Fa4Hkgs6sHwcKCCfzqPekzMjhmCrnGP1/E0CuYVnbJ5rby4GQEYngH3rU8sCM4w23I6Z98k1AoJtyyjhTycDPvVuKZVhRT67iDzmgTKckahVAKlguPmI9R/jTDbofMQdVOfUg9+adJdwtK6xgBcBcYAA/D+tJbStJOUTEYyScY5/GnZ7iuVbiNYrZ9uDK524I7HvmqqGSGcxTSo5YAgDoo5+X61YvZNxIhYkbhhuxP8AhWXdI8LNvljY42gA8A+me/Tr2q1G6uTOVtGaM2ZNm0nAP3SODSIWYjYCilcccc9TzWXp93dmQLIrn72W4Gwe/oa11YggFQRnJXOMCk1YIu4sVrvCMwHPQA5JzzVaW3jeVi3A3YOASQAM8Vcw6l1RyrsME9Dwe1SlE8rDEAknjOCe3+NTF2Zd11K+jafLdQiOEJlPmYFsEduc9aup4fu8AGEEHjBdc4z9aqRgvMI0QBN3BB4PqSa33t9Lt2ut0VxM9myh28znnuB25p77mUpNPQwhZy2kzxXAwxOCMjp14Pr0oq5qEMdtdtHCpji2Bl5LZBAOT70UmWrtXObmnWTarbm4A3Y6e1TCdAg+cEDtjpWNb3kZJUsR2IxxU6XP71tvygDlSRgjFKxKkbJkO5S5QqBlWTGaZLMoLDJfJ6Nxg461SWYSKgkAXb1HGAKkBWU7fMyM85z+YoHdMeHQMxLlcf3hRCMxtuXgHjn73pSlZPNCg98A5H505GOWPAdSTgjg0D0ZKz4U/MCG7gY/WpckH5GYuo7dMVGGdtqjbsAGVY5PP86XymUHqMjkHg89qViki1btvVSzsMseDRLKcnPAY7e/5n8qgEXzRhiRtByRQZQoUq6bQTjI7UnEanYsIV8g79xfnkDG78KSQguYywV1GAd3K0xJlZOem45I4xn09apTOUnAdVYAnnuP/rUlE0UrmgtuGPmHG5Rg+vvxUp3OnOQu3O40sQyhcAqc4PGQKlOGDFRyBxnkAgUrBcijeNZAcFSvPOMnsOKfBGG8xSnf73cVSAuGc5XrkuSevPTParcajy+ScYzj1PrmnYuUVuhksBY/dYsBgsPT1qucp8yKoLHDMTnI9RVx7jCkMdrDAOTjj6Cs6+cbcuxWMdUXv/SmtWSl3FuWRxIYwRtGCw6CuY1SIyzKmWLYzuYdD3NazXEYSQxtufGQink1BM6/JKxIjVtpDAFhjrn1Faxi1IxnaUbEFoskESKA6xlclgMAn3qG5WEGRc4Y/MvP61p3cdiVWS0aRmI6E4GD29OvFV7yFCgZvLOOpVugHWtOWzuZttxsUlWVhmEMybcFcYGfarel2EVozyM3+uAXb/dH+OauWCorMshLxnhSx9fp+NIsqJJINobADZIIznI4/Kq6BTiotS6l0yIUXadzqNuHXls1Thctc7fIOxZCD82ASP0pkg/0sXIYhWGSAwOT057irttOHV2nAC55IHGOM4AqG7ao6JPmRn3pLzPMwGHG4YOcj3HtU9kTvIWVlyOvpxzTJtjSskkZXHBTHGM8D6VYtnELJ5YAIHytkHac+vpiqZilqToUWHcsUjEZBdjge2M9/WrGm3kUgZTGhVRtDAfdY9MD39aoG5VJAZcMJVI3lvvfWq9xciCMSWytJGxCFQATjjoO1DdkUWzMFeWM+bgIOVwAuT0NZsdssG1IyxZRyz9GHfH+NXI5MSs7OqtkqoY9cj34qpqL+dGmJG4+9t4De4/lTjYyqrqXImYYERVuc56/h9KUPbXd15rMxYYBjYYUYHGKyUXai7lbb2IPGPerthO1ucqCQSeqg/8A16q6Mld6MdrcklxcW/lzx7QuGjYbNo5+YHueMe1a2nt9j09RJJ8+wHfgsM9s/wAqxoWkivTcK0ZXgsjLlG9/arStJNdecZWVjnzokJxkfd+g2mlN3jcujHlmdVazpLbq6vy3O3PT6UyY/Muwnap5AbqfeqMOIVCw4QDkDoPzpxmVMAMAQeR6Vy3TOpxsy2824Ft42nkY7HvRNEXGIyAzLlsDpmqVtOZZnCsu3BOMfpVwvjOWIxwPYUCKsgZXOAWx909wf896jN8yjb5yiQ8hW68dhTrq5UK7KMKCPm71x015bT34mEgMsakgdgP8/wA6uCuZTnY6ObUSt6EA3EqTk8YHfNW4Cr8DaEA+8OQPauPW5jKcyFp/4RnnPf61r2GrL5BIUkqAgBQgEmqcR05KTsdG48wHcSMf3eM8dPaktnjTDsXUH/OKq28jyI3zjBHGODVoSGQxq4wAeFOOKxkb8tizDlZcq2cknGcgdycHvUjSI0akl1DNnOMnA6VWN0FJAXrwPal3tlzIcHPy/SlcTRJJjayYwxGSCf8AHrSR3CQQuCByAMAVEpImOQqn0HaoZ5kTI4wfwJ5oTJ5bkufL7gBecjpn096qXdyXkRFwXY4JbufQUrOpyRtPGDxjH4+tU78Kz5dgrAc8cY+tVcLETXcyRPDtSZC24NwOQeuRyR7UjTyFzI+YwAcAdOaqie3hfdwI0I47sc81m6nq1szPDApj2gsAT8zd/wDPpWyu1uZ1HGG5qXTSuGVpMI5HCcYI6D2rM3OQ2+J9sagZ3ckA9fes8amwt2B+d2PHHA9M1Wm1GWQBY2BT+IAHr3yfWqWnUwnV5jflntoTuiKiRvvIP89a2YJ9kYkK7pByB1/D6Vx+ln7RdowX92gyxOSS3qfWusRMR5U5449wP5VlN3ZpTd0Pnu2CB4sFmbqOox6U/wA/zFHVjnlee4/nWbdXZEpEYbk9u/tUkU5xkAhgOe341BqkSzXcVpsD9G+VXxjca3muriDUlW7ezzNCscu/7oHUF8dwMVx+pKzxRunmBUILuOQOeCfSuidrW9T7Xc2WqJM33kjhyGb1BPTPvVLYiTSeuw/V5bhb6T7QE8wADC/dAx8uPbFFUri8lvL5pJIXtwAqJEw+ZVAAGc0UmtTWOyPMo9TThlbk9xV+G/RuWPfg46V56rEHKnpVuG9ni5VjtHY13ywUuh4MMaup6LBfE8ORg8cdKuxXf9wlCe2civO4NYlQAONw9RV+DWgTy+CeoPGa55UJx3R0wxUXsz0CG/DHZKFdhwN3Slubhy6bFfZnGAe3vXGwazGV2tIB3yTzV2LU4zhlfPHYjNRyNdDdVvM6+CZljCNxKOAR0Ax709rnKDL7icZB5x9a5Kzv0eZ42uCTuyBINhX/ABrQF4kT/MxKt/d5xik42LjW7nRRTZRcjgdc9BVkiHy1dskgYOBjvXPRagGOJGcZ5xj/ACM1Ff6lPGLc2kfnKW/ebyQT6YpcptGcX1N6BikrfNuLfw9gBSwSbg6nO0HqR+NZkV1hd7g5zkqBn8aSHVbdZhE52uz5ye59KXKHNZ2Oilk+UYPHfuKfHKobKyYUD7uMZPvWUbkxod6gknHX5sfSoLW9M05G3ChiM/57UnAvmN9rhQxGdwY8g0xp4XhIjB2/dJ649qoahMpsztyGyeuc1l211sGyRiQeVwc5HtS5RqSuaNxdJDLtKAlht5PWs7Ub3fEd2305Ht/kVQ1cs7pLFlxEMeXg8884xUCFrmFSqNlCQ25SCPUc1pGKuFap0iSQ3ZYZCgDAHTr2H4VJcXDSGORmIIADLjpjisS61IWl6YjA5UkAAdcetWjcHzcohAQHJUDB9/atLI4lN9S99rKHZtBbHBwMVbgJeOJpEDgHBbIG78PrWQ74suHD7mzjGPyp0BlEuzd86n7mfu9+fb2p7gqnLubwaSRX81MqDxjt7etSTxr9nKsmzdwXyT+vrxVI3BijwS3HG4dfw/xqYO75ErKrD5tpbnjvijY6k21qKITFw5wwIC5TlR9KntJTOdpUYVumMZJ/pUKXqK2ZEMjEEsN2OfU+tRQ6kpZY3jVi7EDC4WMf1/GobNI6K5Yu5nlDFF2s7bd5JG7t9KdHNCUCykMeASHI9+RWI+tCa5e2aOSU5I4fG33xjgYHQ/nUkUzySSuyhEB5YYA6cZHerb10MozT1ZZvJo0ucl9xwdoLfqfpWzpNikGnh3AZyc5Jrno7dJUkMh+cEN/eyex/rW9YzubUIuSucLuGK527s3ilcg1OFDyq/KG371OPw+tU7u6VQG3KGBzgnv71DrkjA4L4IYNkevTHHrWfeXDJbCGGZBdFQAxAHTrmtVEwqV1GTRsAxSSZkUBj/EmMEfyNW0MBRxGm+IcKc4A5/wA4rkLGV4mxrLwxRlCUUkk59sdK0Le/iijZrV5JYcjaV6A+3am249CYThMt6va3E7GW0ZgT8pQvj6ZNP0ZZNPtZZpj5yAbvlI+c+mfSptNkMtnvGFDk5XkgfjVS5s/I0+SOJ2bPKtv6c5IqOdM3UbPmidBYXxurUSiEb24Cr82D9arzazbwI8jhWZTtXfwF/D61mG4aTSobW3ASPALug5J9M1lXht4nE0qAxI+Mlsn8qS30FVm1qzo7bUmaVmQYjP449v1q62p2+QscjNISQ6Hse+Ceua5a6v4kubnyozIAoX5T93A/zzU1tbK6rMjFWZc7sgU3qTGaaLGva+ljdx2qxPcykbiqtjj61lPPbSyy3MURVzjeQ3XjqT+lR6paO8scgZWRRhnHNUi8u5liO5jnaQfvGi9tDmne92XPtLH97tHXjgDHtW/ozz3sYnICxqDlgB83/wBYVzWkWLXc6bvMe2z8xJ449u5ruovLig2YCBV2jAHHoMVMpvobUE46lmF0ghGzLFRnJOM/hUkcjFN46j5gvXNZrdlKuMnO7OAPwpyXLhDsI/uhWbtWZ03NaK4UHdJtdtuSV4wKR71XibcWXuM44+nrWS1xvdt7ZbuT2H1qISBn/dvgDBAPr7UhNmwbvqqkDI/GqR3EAlsd/wD69QNOwbBPA6DNQSynbtY7cc+vNOxPMaUsxSLITc7HjFU5Zx5bbgWKr/niqTzbj1HU5Hqarzy4DAHIz8zGmkQ5oytRui1ygjdlI6AHgn6mspsNdqwBdiOSDkZ7muhlgSTn5QeoJGf8/jVecR24C/u8g8sw71rFo5aqc3e5VtrF5I2OV2lcDvk9hU32ELIiuxGBkkNwv4dzUiTeXGzZ+Vjnpj60scrSne7KvbPoP6Ur6iUUlqWbFREcxjy1QY47+5Fai3SgAZyvrnisL7SqpsGQvQEc4HtVdrycXCgCMQHlix5/Kps2a+0ijoJJkLbio+XrmojONwYs23GPpWO16gAkZhuP8veqlxquSx3qq/d4Iy1NQb2E68Y7s6WS4JiaDzGCyfK4B646fWujluYLGRbWbxDfCRQAw8vOw46HmvLH1kKMq5B65zk5rsI531SJL680OdrmUBtqXSQiftu2N83PtW0aE+xz1MVC+5tavbiL7TPHeyXc0GwzCUYO0/dYHPzCiuF1LxbcFNRglsGt724dY5MtgRRpjEYX196K0+pVXqkRHMYLRs83XB7H2p454OPrTeg/GnDA6V7NjxGxcU4dQDQD60Z9qBDsDIz0pUOPu/J9KTPTNKCB1pOKe4JtbE63E6jAlfHQAtnFWYdUuUPJD445FZ4OR1x7DpTice1Q6NN7otVZrZm5b64RxKhIx2NX4deCj92oPHriuTOO3FOGNw71hPBwfwnRHGTjudfc6lczRxmzeKMt98N6eoPapYbxpgba6gEJyCsy5ZmI75NcfDNJEcxsV5z7VettSmiIJbjk/T6VzTwtSO2p0QxcG/eZ29/fS7EEcZk+X1wf/wBdS2E0jRIZCR8wIzwAcdB+lctZatEJQwuHgfIGT901uwyqFyJ1nbP3vMDZrnaa6HZCpGT0Zb1wXk9vGLGRkaM5dOu8emfQVX1EzSwWxt1UlQS4H3l/xp32w/Kh55BAGfxokIIYMCOAG7YH9KzTNr9RujyyNIEfgHJ+ZNvP+fWlubwwXEiPIQ64BYDg+mRVSzgit7wzrJMwPAUjIB9SfWrZj3v5ksaOh7sD/KlYanpYhnnhkiLuDIWbI25ByPrUJhdNojGA/RGOSM9s9MVLcDypDJHEBE+0hlALL68VUJDzHayncOHQYBHuKL2IdnoI00wlbcvl7flA+707D3q3abl2yAjzFOTz7d8fWqr26NMWkVd6gEgvw341PLcxqEKNGFRSSFH3vXFWpEctnqakF47Sb/KUyEgDzeCPfFLeTFZHkkKxyNwZM5J/HHArGg1GGMSeYBIrdycYHuanW8F1GpORtGQQM7l/pSOj2i6FqELNOJJn2xe5GBV+4ubb7NsMRER4fEhUkexqnC22ImWKLcBwWGT9MdqmmtjKIpCxDDBKAbd3qB/WpuWtjLM8H9pOYJNiEYjyTuPtk9fxrYm06f7MBCUQ8nawwPr9ar3F1bQNIz2qvLzluOD/APWqlZ3kYmaQRyyy8/J5mFX8T/Sm11ZMOWOjN7S7SaFg9zMrIq4Cryc+vuavPKVjcKQVboepHvWbY3DXG4FDGTy4zkgeuaui4SKHeqrtAxlzgZrLldzqVmroytQh2xb2k8vB/hzn8qwbm2RrsTyFHhiUAKRj9a6C9lWT98pVpACAeuD3x2rBvlVZwZRkt0BOASPpx71afQ5alNbj5LC2v3juCJSWbCshwGHQA+laraebG3Ij2BQOV4O0DoPpWV5qSoqWo+71bOQT9KsRt5SDzJnO/qgGd319Kd2xR5VqPsb0rPCI3mSCPhuONxOSD7+9dADE4clssRxt9TWLZxop8x0VGz93PCn1zV1J4QqsDuPTj3/rWbRvTemrINQv2s7ORwqkJgJ3znjNYNxqTXVgkXDsDl2Pv0ArS1FDcR7BIuCQdgOc89Dis2awWF2lNwx2HOw42j2OO1aJ6HPUvJ+RetNNZtOBM6pdSYZ3bkgHt9fep3W1tPnJlBA2xgNksf5CuZu7ieO7WeGUyFziZidoA/Gp9PuXmAPngqGwidePemkiFVjHRIlvtVnubmIWYaNF4ClQdx981rW0FwZI3mdC5Xa2OBnso9v51WWRi24hREmXJ4H4D34qBrx7iWJoImZw2cKeTj69KJO6sgTSd3udVZrHbICeR1Ofr+lK94tzPhoyIg2VHcVkaldMunP5zrEzpgsgLFSRjj1rJsSbeFEtlllWQBpGIw2enPoKSgae2s7I7IXaHO1+pwAG6mqxmCBztyWJOSf1rJgeO0jVQQTjj0FVpdSAz8yqM+tT7NvYHXUfiN17rPGAAOpJpouwS5X7oHUc/rXMyazbKvDKx6nknNVZtdBB8pXxjoBgVrDCzl0OeeOgup1cl4q8qeAemc5qN7wBQNw3EZ46Vxs2sTMfkXGO5bv3qvJqVyy4DhR7CuiOAmzmnmMeh2D3uckMCAfxqvPeyjPkoGckD5m4/wDr/SuQNzOwI858YxgGo9zEfMzHHua2jgO7MJZg+iOtl1aMIQ8i7iMfK3AqpPqdu8o8xo3QHgZyPyrm/X1NJ0rSOBj3MnjZs6CTWYz/AHm7HAwKjbWjtJVWLEdB3rE/h680ZwT71osHTXQzeLqPZmi+qznIGAD1quLqc8CQj8eaqk56/wD66cPrya1WHpx6GUq9R9SZ5pHJLOefy/Km9Rng/wBKjyAc0u7n2PpWiilsjNyb3HK2CDgMAc7fWus1rThrupyanZ6tYi3m2sPPn2Pb4AG0r14xxiuYtrS4uywtLeacry3lIWx9cdKlbRtSIJOm3pOOP9Hb/CmwRd8U3sN9rMk1rIZoljji84jBmZVAL/iRRT/GcYi14IIxGVtbfK7cc+WM5HrRRFKyE9zkwOeopT7gUdgD1pcetBVw6cD86ByaXb6frSge1FhCdaXGcUo4FAosAL0OevvR0wQacAcClPuaLANWnfQfWgenal2nt2osAh6d6X60HjFLzjjFFgHA9fpTQqqcqqg9cgYoweCKX2PFS4J7opTa2ZaS9mUkhm5564xU39rXSSAxEADjb6+1UBnoaX+8BWMsLSl0NY4mpHZl2bWpwFAQLKDjeq43VfstcJb/AEiWWI7SACSVb1+lYeT2pcDKkqCQMDPYelYywS+yzaONktzpHuI7sqrThwDyqOMD8BTbaWGKZo42beg6NFlfzrnSqbXUBRu4OBg1FFBHDJ5keUf13HNYvBSWxqscrnV3FyF58shRjIxg/nVCTUVdgVjXK/eCjGR6c1jncTuMshfud1ADbsmRj0yCBzS+pVCnjIs3hdWygtNGAx4HzAEfnTbjU4oJkUwyvIuGXdLgH8axSWYDc3A6L2FOeWVx87b+D94Zx9KX1Sp1BYuBt2mvSG5827mAUnIiMYwB/st2P1q0dTkMvmkyKxw3ynBHp069TXLoWVw2QcdmHFTG6cKVVIlz3Axj6UpYSr2KjjIdzauJZbpmknDmINkEH5vz9KiMkTyBoUAVc5B4J981ki6uF4804/3jj8qebybaRshJ/v7QCfr2qPqtVdCniYPqdLBdrHbAEhZCAeG6flTjqX228WMtHcQgYLbsFcDp/wDXrlZbh5F/epvz/CrlVq3a6n5CqggQRgY2jnFDw9TomaRxkVpzHWLIYkIhhADDG4cBT6+9Y5ae2laSVxKgHyoy5wc/yqkdZYJ+7BBB4PpUMmqSMpGXye4NT9WqfysqWLpvqbEF0G3nYsRLYwBgn6gdKrvOPtDlAQqnJJ7j0rBL7pS8jPID74NPac7MKNpPJycj6VX1Wr2MnjIdzoIr7ybjc48xG+9kkhcdB6H6VNHqBkYbNzKeAN2M+wFcqJH4yxAPYdKkF1KFx5spOOu7H8qf1Oo9xLHRXU7VbhYx87FW44C9B6Gs291SF3a2tp088HDKik4PvxiudF7MsZSNwoI7d/rUfnygcSMB3A4rSOBl1Yp5gnokaFxaqshLSKzf7YLZ+oqWG7jgIEancBnO1VBI7j3NYxYt94lj7mj0P5e1bRwVt5HM8a76I3W1jAIKoxY5YuSwA9h3NOfWV/gWRT/FjqaweePSlwQP/r1osFT6kPG1WaMurzO+5OCP4m+Y/WqzX1xIcSyu/O4DOAD+FV2PTHpim+vY4rSOFpx6GUsRUluyyby5P3pnB9jULsXbc+WPqTTecA0HrWqhGOyM3OT3YDg+9GdowenrTc4yRS9e9VYm44GkOcUAcUE+n06UxCr1J/CkPNAz60NnHNAB/nNJ0GTSf0oJGfftQAA/hSk4A7803PPFA5/nTAUGl680mTn0o5NAATnHp3p2aaBz0pe/PWgVy1Z393Ys5sbqa3LgbjE+3d9atjX9Zx/yFr7/AL/GpdAt7Q22p6hfwG5iso1ZYAxUMzNgFiOdoqe4srPWNOnvNFga2vLdS9xY7i4Kf89IyeTjuKltX1GY9zcz3cxmuppJpWAzI5yTjgUVo+LraG01oxWsSxxG3hfav95owSfxNFNaoTRzP6UopOO1O7+tIoWlXHJpoGScUoB6UwFpRj8utIBzT+1AhPcUo4ajjHPSl+oB9KADFKOlIBgZzxilA96AFIHT+VKPypufX/8AXSjg9egoAUDuOlGcDFB5xmj68UAKOvvRxu9aTPPUZoByPWgB386aOvFHAozxng0AOHvg0vBBxmmA8849qVfc0gF7e9IevHbHSndqTrQAh780Y96PypOp+lACDpjJx6UtHejt2zTGLu7c/hSZo7ccUfjSAXvTcmnY+lIRxTC4o9aM00HAFLjtmlYA5yKM0Ht60h60WAXnHNA5NA5HNNJOemcdaYXHY5NFMJyc8UpzQApoGCB69qOvX0oxkYwKAFB9OlOHBIqPnHvTgeee9AC9uRzR260nHT05o56j60CFJ46D60cDOPzpM8dKQnIAOP8ACiwC9zxSDGTnNLSH09elACjj6UduD3pvfgD86Ude2KGA/tTTn8KM460E5PTFACE0dKG6AUnpTAMcUZwc0DiigBQaXp2PvTQck8YpckkUAKf880d+9Nz3BobjrQI1/DsmrQXck+iQSzuF2SokXmKVPZl6EVLa6T4htLtLq103UYZ0YsrpCQQf8PaqOh6jdaZqUVzZbmkB2tEM4lU9VIHXNXryHXg8s0dtq8FsWLKrGRto9M96l7jRX8R3F/d6vJNrEJgvSihkMewgAYB29siis2SeSaQvNI8jngs7Enj3NFNaCZVx7frSjNO+nIpKB3DHXj60uCMdhQB1zSj3oAMjn19qOn1zS4GeO1IPT1oAO/WnDrTcYPNKcZ45oAdnp6UuRkelN6Dml9PQdqAFJznjp0oz+VHX60Ef/XoAOeKdzx+tIf50Y7A/lQAnIUdc0pznJzxQPWloAQ9vWg9eBQOvWlIxQAdhmkH3vag0gz+FAEgxjnikBx0pO3saOlADjjr60mABjrSdO9B5FAB6H0o+g/8A10ueBR0NAB3o796Q8UEHFAC5z2pOo5zijn8aU57UANwRzx9KU5NITycfWloAUnI+tIRyPWk96XtmgAJ7UDPFABwc0vTHtQA0jPfNJ9KcMdqQ+1AB2HrTevFO65pAOaADB78mlAI/HrQSMe9Lux0oAXAz3xS5GabyKTPGcUALzz6U09qUdsnrQD7UwEPIwTRgj0x7UrHnFNPXANACk+lHY56UlGTkUgFzQMdqaTz0pRweelMBfWgUh4H1oHTGaAFPTijn6U3of60Z69c0AKxx7mjPORTc8k/lQCd3HWgB2eMYoJyaTjNJkZPrQB0ng+Zl/tKKzuIrXVZYQtrNKQoHzfMoY8KxHQ1bj0rxik/mC5uYmBz5r3o2j3J3Vj6Da2MlvqV/qkUk1tZxo3kRttMjM2Bluw9anvNOstT0qW/0FZY2thm6sJJC5Rf+eiH+JfUdqh7lEPjC4gn8QTvayRSZRBJJGuEklCgOy+xOaKZ4rtLew1ryLNNkP2eGTaCTyyAk/nRVR2E9zIowetIT0x3pfrQIdSDjNAwaCf0oABxStQSQBQDQAduetKKbk5HHWjPtQA7jAopF6ml+lAC55BPWnZ556U0HuKM45FACntQM470Z9entR8pH06UAL29KO/HQ9KQev6CgHjtzQA4dielBHFJnNGcjpigAFGPaj8KCe1AC5wMdMdDS9P60zd3pR+poAd2pM0Uo4+lACUpIpKCx5NAAR2FHYkUvXpx9KTjHFAhT7UnfAoz69KAeBRYYhHJpMkGnHtQelACDqPel+n60mcn3FB6H9MUAKT14pOuaM4zRnIoAMY6Ug68mg4JGSeKGJJB96AFx0AoPygH+ZoDYOe9I7ZxikAfTmjk8mm4GKUcc9aYC5P8A9ekzkGkJ5pO3NADg1HrzTcjPH0FHSgB2fxpAfwpOo7EUhPbvQBISB3pmeetJ2HvSUwHg9xgmjJzj+dM4/wD1UoAPuPpQA7tTSenqelL2pM+tAAecfSl6dabwaUjjNAB3NHvSE8ig9aAFz070Hk/hTc0E470AXtJ1S50q4eW2EbiRPLlimTfHIvXDCoLDULixvkurGbybiMkgrjAz1GO47YrQ8OWUd1LLNPD9oSJo4o7fO0TTOcIpPZRgk+wrSt7yS61G8sJF0i6hgVikCWwjE+3lhE4GVOAcEnnFQ2ikYetanNq+pNe3KxpKyIhWMYXCjAwPwopmt2cdlfGKB2ktXRJoXYc7GGVz784P0oqk1bQRWwQaUjuaDSdzTELnnkUdqB1pzfcNADfWjntz9aOw+tI33Se9AC+gzmiiP/Vj/dFC/fNAB/8Arpyn0NM9fwp7/fakACg0h6U40AC8f40Z65H4etI3b60np9aNwH96Q9SDSJ/qz/u0Dp+NCAUN04pcihfuigUwAkHAo4zk/lQO30pP4F+tAkLg4wKP50g/pSnpQMO/vSk/j7U1/wCtKetIAycY9aUdumaY3SnHp+NACg0A8801u30oFMB+ewpAevFN/v0vb8aAA+o70pb1x/Wkf+GnJyefWgBvSjpTG6mnH7tIBd3GMUds5H5031pB1FDAeTnimgnH0o/iNB6H60AKDQSSBTW+5SjqaGAfWmk/X2pR0NI3X8KAA9frQc5JFB6iigAPHWlHT6U3+E0DoKAF/L2pM+lB+/SGgBT1pO1L2FBoAQdKXPcUnYUD79Axc5HvSZz160fxUUCQDgH86XJ79aQffFInT8KLjFz6fmaM0i9KQ9aLgKfagnHGKRf9UfpUan92PxpoDa8P6hHbNNBczNbxzFJEnVd3kSoco5HcdQfY1tkQxSy3QTRrEyBg17DeGbaGGGMUPUMQTjPTPauLHWkKgOMADioceo7l7Wr5L7UGlt4zHboqwwoeqxqMLn34yfc0VnmimFj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory vesicles and crusts are present on the extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tense bullae, erosions, and crusts, often in pattern described as &ldquo;clusters of jewels&rdquo; or &ldquo;string of beads,&rdquo; on skin of patient with linear IgA bullous dermatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32809=[""].join("\n");
var outline_f32_2_32809=null;
var title_f32_2_32810="Postoperative management of the critically ill obese patient";
var content_f32_2_32810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postoperative management of the critically ill obese patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Kevin Thornton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Richard H Savel, MD, FCCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Michael A Gropper, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/2/32810/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/2/32810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery is appropriate for patients who are at high risk for, or who already have, medical complications of severe obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Bariatric surgery leads to more substantial weight loss than conventional management, and has the advantage of being a long-term treatment for a chronic health problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Surgery for weight reduction is an elective procedure, generally performed in young patients, and the rate of postoperative admission to the intensive care unit (ICU) would be expected to be low. However, severely obese patients often present with multiple comorbidities, and those undergoing bariatric surgery may require ICU admission or prolonged hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/1,8-12\">",
"     1,8-12",
"    </a>",
"    ]. ICU care is most important for those patients with a body mass index (BMI) &gt;60",
"    <span class=\"nowrap\">",
"     kg/m",
"    </span>",
"    (2) and severe obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The care of the critically ill bariatric patient will be reviewed here. An overview of the surgical treatment of obesity, and a general discussion of postoperative complications are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely obese patients, who have the most to benefit from bariatric surgery, have a greater-than-average risk of developing several postoperative complications, including severe sepsis syndrome, skin ulcers, wound infection and dehiscence, and venous thromboembolic disease (VTE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/9,14-16\">",
"     9,14-16",
"    </a>",
"    ]. The annual incidence of severely obese patients requiring ICU care is expected to increase in conjunction with the number of bariatric procedures performed (",
"    <a class=\"graphic graphic_figure graphicRef71694 \" href=\"mobipreview.htm?15/37/15965\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/1,8,11\">",
"     1,8,11",
"    </a>",
"    ]. However, if these patients can recover from their critical illness, many will have a much higher quality of life than they did prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caring for critically ill severely obese patients is a challenge for the entire ICU staff. These patients are often difficult to intubate, and gaining vascular access can become a major source of frustration. Even routine aspects of care, such as monitoring blood pressure and moving the patient, are complicated. Furthermore, many diagnostic studies are impossible to obtain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of limited quality. Given the difficulty of providing care for severely obese patients with a critical illness, transfer to a hospital with appropriate resources and significant experience managing these patients should be considered. Severe obesity is independently associated with increased mortality in the ICU, and as the incidence of obesity increases in the United States, the number of obese patients requiring ICU care will also increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8,11,20-22\">",
"     8,11,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of perioperative or critically ill bariatric patients is similar to that of nonobese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/23\">",
"     23",
"    </a>",
"    ]. However, technical aspects of providing nursing care, hemodynamic monitoring, vascular access, proper medication dosing, and nutrition all require special attention in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obesity bias and care with dignity",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the greatest challenges faced by the bariatric critical care clinician is maintaining a sense of dignity in an environment where privacy is at a minimum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/24\">",
"     24",
"    </a>",
"    ]. The first step is to acknowledge and manage any prejudice that may be present in the ICU staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The second step is to take care to completely avoid any inappropriate or unprofessional comments regarding the patient. It cannot be overemphasized how important it is to build a supportive relationship between the clinician, the patient, and his or her family. Support groups, for both the families as well as the critical care staff, may often be of great value in these situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/19,27-29\">",
"     19,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nursing care and equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moving the recovering bariatric patient is key to preventing morbidity from skin breakdown and decreasing the risk of venous thromboembolic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An intensive care unit caring for bariatric patients must have the proper equipment, including special beds, lifts and, if possible, a dedicated \"lift team&rdquo;. Discussions must occur among the bariatric surgeon, intensivist, and ICU nursing leadership well in advance of any bariatric ICU admissions, so that the equipment is available when needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/31\">",
"     31",
"    </a>",
"    ]. Such an approach also allows the nursing staff to receive the assistance required when moving the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a proper-sized blood pressure cuff is essential for accurate hemodynamic monitoring in obese patients. The length of the bladder should be at least 75 to 80 percent of the circumference of the upper arm, and the width of the bladder should be more than 50 percent of the length of the upper arm and approximately 40 percent of the circumference of the upper arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. If too small a cuff is used, the pressure generated by inflating the cuff may not be fully transmitted to the brachial artery; in this setting, the pressure in the cuff may be considerably higher than the intraarterial pressure, which can lead to overestimation of the systolic pressure by 10 to as much as 50 mmHg in obese patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend placement of an arterial line in the majority of patients, to allow both continuous blood pressure monitoring and access to blood for analysis. Arterial catheters can often be placed in the operating room prior to induction of anesthesia, avoiding the femoral artery if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placement of central access catheters in the critically ill bariatric patient can be difficult. The usual anatomic landmarks are obscured, the distance from skin to vessel is much further than normal, and the angle of approach may be too steep to allow cannulation even after reaching the vessel. The use of ultrasound to assist in the placement of central venous catheters is strongly recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripherally inserted central catheters (PICC) should be placed early in the ICU course for the bariatric patient to ensure reliable vascular access, since they can be placed fairly easily, can deliver hemodynamic information, and can be changed over a guidewire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Hemodynamic measurements made using a standard pressurized transducer system through an open-ended PICC line are reliable when compared to centrally inserted catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/36\">",
"     36",
"    </a>",
"    ]. The utility of central venous pressure (CVP) measurement as a predictor of intravascular volume status remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As always, meticulous attention to sterile technique, including full barrier protection for the patient as well as the use of cap, mask, sterile gown and gloves is of the utmost importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/39\">",
"     39",
"    </a>",
"    ]. The femoral approach should be avoided, if possible, as an indwelling catheter can exacerbate the risk for developing deep venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Additionally, these patients often have intertrigo, which can contribute to catheter infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic energy requirements of critically ill patients are generally estimated based on actual body weight using the Harris-Benedict equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/42\">",
"     42",
"    </a>",
"    ]. However, this equation may overestimate the metabolic demand of critically ill obese patients, and can lead to overfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/43\">",
"     43",
"    </a>",
"    ]. Indirect calorimetry can be used to measure energy expenditure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/42\">",
"     42",
"    </a>",
"    ], but this is not widely available, and may be difficult in patients receiving mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previous studies in critically ill adults have shown aggressive glycemic control with insulin is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a large international randomized trial showed increased mortality associated with intensive glycemic control (target serum glucose 81 to 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.5 to 6.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    when compared with conventional therapy (serum glucose less than 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/45\">",
"     45",
"    </a>",
"    ]. Therefore, it is reasonable to maintain serum glucose levels less than 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    but tight control is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely obese patients with OHS complicated by baseline hypercarbia are at risk of postoperative hypercarbic respiratory failure, and opiate administration may increase this risk. For these reasons, the use of epidural analgesia for postoperative pain control following laparotomy should be considered in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WEIGHT BASED DOSING OF MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based methods for determining appropriate dosing strategies for critically ill patients with BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    are lacking. A basic appreciation of how obesity alters volume of distribution and clearance of hydrophilic and lipophilic drugs is necessary for determining appropriate dosage regimens. In general, obese patients have a larger volume of distribution (Vd) for lipophilic drugs, increased clearance of hydrophilic drugs, and a decrease in lean body mass and tissue water, compared to nonobese controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8,46\">",
"     8,46",
"    </a>",
"    ]. Drug metabolism via CYP3A4 is decreased, whereas clearance by glucuronidation or glomerular filtration is generally increased, in obese compared with nonobese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/47\">",
"     47",
"    </a>",
"    ]. These changes predispose obese patients to both subtherapeutic and toxic responses to medication.",
"   </p>",
"   <p>",
"    It can be difficult to determine whether the initial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintenance dose of a drug should be based upon ideal body weight (IBW), total body weight (TBW) or dosing weight (DW = IBW + 0.4 x [TBW - IBW]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Ideal body weight is an estimate of lean (non-adipose) tissue mass for a medium frame non-obese adult. Dosing weight accounts for partial distribution of certain drugs to nonlean tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of the appropriate weight used for dose calculation of medications often employed in the ICU include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/15,40,48,50-52\">",
"     15,40,48,50-52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ideal body weight (IBW) &ndash; IBW is also referred to as standard (non-weight-based) dosing. IBW is used for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta-blockers, penicillins, cephalosporins,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , glucocorticoids, H2-blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      (maintenance dose),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      (and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      for induction dose).",
"     </li>",
"     <li>",
"      Total body weight (TBW) &ndash; TBW is used for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      for optional loading dose only)",
"     </li>",
"     <li>",
"      Dosing weight&nbsp;(DW) &ndash; DW is used for aminoglycosides, fluoroquinolones (individual agents vary), (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      for loading dose only)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calculator",
"    </span>",
"    &nbsp;&mdash;&nbsp;A calculator is available to obtain a patient's IBW and DW (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    loading dose, a different calculation is used to determine Dosing Weight which is listed in Lexicomp, section &ldquo;Dosing: Adult&rdquo; and &ldquo;Dosage adjustment in obesity&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     \"Phenytoin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-infectives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individualized dosing of anti-infectives for patients who are obese is recommended given the potential consequences of inadequate treatment in this population. Dose adjustments should be guided based upon therapeutic concentrations whenever available. A consultation with a critical care pharmacist skilled in anti-infective therapeutic monitoring and pharmacokinetic dose adjustment may be helpful and is suggested.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cephalosporins and penicillins &ndash; Limited data for cephalosporins and penicillins suggest that doses at the upper end of recommended ranges (ideal body weight [IBW] based) are appropriate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/50\">",
"       50",
"      </a>",
"      ]. A small trial of bariatric surgery patients receiving operative prophylaxis demonstrated that a 2 gram dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      was needed by obese patients to attain serum and tissue concentrations that were equivalent to nonobese controls receiving 1 gram [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38519?source=see_link\">",
"       \"Cephalosporins\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a weight-based regimen is used to dose beta-lactams, IBW is appropriate, however the upper end or maximum",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dose should be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/50\">",
"       50",
"      </a>",
"      ]. Because beta-lactams exert time-dependent bactericidal effects, these drugs should be administered frequently (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      intravenously every four hours) or as a continuous or prolonged infusion where indicated. IBW dosing regimens are suggested for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      and alternatives &ndash; The initial empiric dose of vancomycin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      should be based on TBW [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/50\">",
"       50",
"      </a>",
"      ]. To attain rapid therapeutic concentrations, a loading dose of vancomycin is suggested and maintenance dose divided every 8 or 6 hours, rather than a standard every-12-hour regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/51,56\">",
"       51,56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link&amp;anchor=H10#H10\">",
"       \"Vancomycin dosing and serum concentration monitoring in adults\", section on 'Obesity'",
"      </a>",
"      .) IBW dosing regimens are suggested for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Aminoglycosides &ndash; Aminoglycosides are hydrophilic and should be dosed initially according to dosing weight (DW) with frequency of administration determined by renal function and adjusted based on serum drug concentrations. Use of \"once daily\" (consolidated) aminoglycoside dosing regimens in patients with stage III obesity is controversial. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link\">",
"       \"Aminoglycosides\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/30/8679?source=see_link\">",
"       \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluoroquinolones &ndash; Optimal dosing of fluoroquinolones for obese patients is not well characterized. Use of dosages at the upper end of recommended ranges is suggested. Case descriptions support use of dosing weight for determining a weight-based regimen of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      up to 800 mg every 12 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48,50\">",
"       48,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sedatives and analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For dosing of intravenously administered opioids and benzodiazepines, it is reasonable to use a series of small standard doses frequently (eg, every 5 to 15 minutes) until desired level of pain control and depth of sedation is achieved. If a weight-based dosing regimen is necessary, IBW is appropriate to guide the initial dosages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    for the nonmechanically ventilated ICU patient, and carefully titrated to analgesic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48,57\">",
"     48,57",
"    </a>",
"    ]. The critical care pharmacist should be consulted for advice regarding appropriate dosing.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are lipophilic agents that redistribute widely to adipose tissue following initial rapid distribution to central nervous system when administered intravenously. We suggest use of IBW for adult dosing initially, and titration to effect for ICU sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/15,48,57\">",
"     15,48,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuromuscular blocking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    should be dosed based on TBW, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    should be dosed according to IBW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of distribution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in obese patients differs from non-obese patients since adipose tissue has a lower blood volume than lean tissue; as a result, heparin dosing requirements do not increase linearly with body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The optimal dosing method for heparin&nbsp;and low molecular weight heparins in obesity is not well established as most studies exclude obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/60\">",
"     60",
"    </a>",
"    ]. The data available support the use of total body weight (TBW) to calculate the initial bolus dose and infusion rate to achieve a therapeutic partial thromboplastin time (PTT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. As a result, the 2012 American College of Chest Physicians (ACCP) guidelines on parenteral anticoagulants suggested that weight-based dosing was preferable to fixed dosing in obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].&nbsp;The initial rate should be adjusted according to PTT measurements after six hours. Suggested dosing for low molecular weight heparins in obese patients is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef65464 \" href=\"mobipreview.htm?8/6/8302\">",
"     table 1",
"    </a>",
"    ) and these issues are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maximum initial bolus and infusion rates have been suggested. However, the available data show that obese patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    without initial dose maximums have an increased mean initial PTT but not an increased frequency of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/61,66-68\">",
"     61,66-68",
"    </a>",
"    ]. The functional heparin assay (the anti-factor Xa activity [anti-Xa]) provides a reference standard for testing the in vivo activity of heparin and, in obese patients, may be more useful for heparin monitoring than the PTT.",
"   </p>",
"   <p>",
"    Low molecular weight heparins (LWMH), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , should also be adjusted according to TBW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/5,62,63\">",
"     5,62,63",
"    </a>",
"    ]. Variable absorption of LMWH by subcutaneous injection in severe obesity is a concern and anti-Xa monitoring, if available, is suggested for obese patients receiving LMWH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/60,69\">",
"     60,69",
"    </a>",
"    ]. Enoxaparin&nbsp;40 mg every 12 hours subcutaneously provides effective prophylaxis against venous thromboembolism in bariatric surgery patients up to a BMI 50",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    and 60 mg every 12 hours for a BMI exceeding 50",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Venous thromboembolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest use of ideal body weight (IBW) adult doses for initial and maintenance dosing of intravenous beta-blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and calcium channel blockers. If a weight-based dose is used, IBW is appropriate for initial intravenous digoxin loading dose or intravenous beta-blocker while dosing weight is suggested for initial dose of calcium channel blockers. Supplemental and maintenance doses are based upon clinical effect using usual IBW adjustment methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48\">",
"     48",
"    </a>",
"    ]. The critical care pharmacist should be consulted for advice regarding appropriate dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PULMONARY CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Obesity hypoventilation syndrome and obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely obese patients are at risk of perioperative respiratory dysfunction for a multitude of reasons. Many of these challenges are directly related to underlying comorbid conditions, particularly obesity hypoventilation syndrome (OHS) and obstructive sleep apnea (OSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OSA and OHS can complicate management of severely obese patients because of an abnormally small upper airway and chronic hypercarbic respiratory failure, respectively. OSA is extremely common in very obese patients; in one series, over 70 percent of patients who underwent polysomnography prior to bariatric surgery had OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, patients with OSA are at increased risk of postoperative complications. For patients with suspected but undiagnosed sleep apnea, overnight polysomnography and evaluation by a sleep specialist are recommended prior to any elective procedure involving general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intubation and anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successfully intubating the airway of a severely obese patient can be difficult, even for an experienced anesthesiologist. Anatomic reasons include the large amount of redundant oropharyngeal tissue, small oral opening, and thick neck with limited flexibility morphologically associated with severe obesity and OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. All of these can make laryngoscopic visualization of the airway opening difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From a strictly physiologic standpoint, severe obesity causes a reduction in functional residual capacity (FRC) and expiratory reserve volume, particularly in the supine position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, the work of breathing is increased because of decreased compliance of the chest wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/78\">",
"     78",
"    </a>",
"    ]. Preoxygenation with mask and bag ventilation can be compromised by the reductions in FRC and respiratory system compliance, and profound atelectasis with subsequent intrapulmonary shunting can lead to severe hypoxemia and rapid desaturation after induction of general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H35#H35\">",
"     \"Diseases of the chest wall\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with OHS and chronic hypercarbic respiratory failure complicated by pulmonary hypertension and right ventricular dysfunction, the increase in intrathoracic pressure and pulmonary vascular resistance caused by intubation and positive pressure ventilation can result in systemic hypotension. Anesthesia can also blunt the response to chronic hypoxic vasoconstriction, increasing the intrapulmonary shunt fraction and worsening hypoxemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most obese patients can be managed using a standard approach of intravenous induction followed by direct laryngoscopy. However, in patients with severe obesity or other factors that might suggest difficulty with direct laryngoscopy (Mallampati score &gt;3, poor mouth opening, limited neck mobility, or history of obstructive sleep apnea) an alternative means of securing the airway can be useful. In this setting, many anesthesiologists intubate bariatric patients prior to paralysis and the induction of general anesthesia with awake fiberoptic intubation or direct laryngoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/80\">",
"     80",
"    </a>",
"    ]. Video laryngoscopes and intubating laryngeal mask airways are other useful adjuncts in the management of potentially difficult airways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=see_link\">",
"     \"Devices for difficult emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid sequence induction of anesthesia and intubation can be used, but this approach may carry a greater risk of aspiration if there is difficulty securing the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8\">",
"     8",
"    </a>",
"    ]. Regardless of the specific technique, it is crucial to have a well-established plan for anesthesia prior to attempting endotracheal intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link\">",
"     \"Endotracheal tube management and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mechanical ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Static pulmonary compliance is decreased in the severely obese patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/78\">",
"     78",
"    </a>",
"    ]. This is generally due to a heavy, noncompliant chest wall, rather than pulmonary parenchymal restriction. For patients who require mechanical ventilation, initial tidal volumes should be set to approximately 8",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of ideal body weight and to 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    ideal body weight in patients with the acute respiratory distress syndrome or acute lung injury. Subsequent settings are determined by peak airway pressures and results of arterial blood gas measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, plateau airway pressures should be maintained below 35 cmH2O. If this is not possible, esophageal manometry can help to quantify the relative contribution of the chest wall to decreased respiratory system compliance, and transpulmonary pressure should be kept below 35 cmH2O. The addition of 10 cmH2O of positive end expiratory pressure (PEEP) may help improve lung compliance by reversing atelectasis and increasing FRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21991?source=see_link\">",
"     \"Assessment of respiratory distress in the mechanically ventilated patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be adequately sedated, starting with an infusion of a short-acting sedative such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    . The level of sedation should be decreased and the amount of sedation necessary should be assessed daily in patients requiring prolonged care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. An opiate should be provided as needed for analgesia;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    appears to have the fewest hemodynamic side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some data that aggressive perioperative pulmonary toilet as well as having the patient in the sitting position as much as possible may decrease the incidence of aspiration as well as time to liberation from mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Extubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all bariatric patients should be extubated in the operating room at the end of the procedure. Premature extubation can have",
"    <strong>",
"     catastrophic",
"    </strong>",
"    consequences, and it is often prudent to allow the patient to nearly completely wake up in the recovery room prior to extubation. An anesthesiologist or intensivist should be involved in the recovery room decision-making process, so that arterial blood gas results can be reviewed and noninvasive positive pressure ventilation can be initiated immediately, if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the postoperative bariatric patient demonstrates either respiratory or hemodynamic instability in the immediate postoperative period, the patient should remain intubated and the patient should be brought to an intensive care unit as soon as possible. Subtle indications of respiratory distress in the first few hours to days after bariatric surgery may reflect the respiratory compensation to lactic acidosis, which is induced by substantial tissue hypoperfusion and may be an early sign of impending abdominal catastrophe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Noninvasive positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is crucial to ask bariatric patients if they have OHS and if they chronically use noninvasive positive pressure ventilation (NPPV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Patients who use NPPV should be instructed to bring their machine to the hospital on the day of surgery. We often transition patients directly from the critical care ventilator to their own NPPV machine, frequently alleviating a degree of postprocedural anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Role of tracheostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early tracheostomy should be performed for critically ill bariatric patients if it appears that they will require prolonged mechanical ventilation. Tracheostomy can often be technically difficult, and a carefully coordinated plan between surgeon and anesthesiologist must be designed prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/93\">",
"     93",
"    </a>",
"    ]. These patients may need customized tracheostomy tubes, because of the increased distance between the skin and the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8\">",
"     8",
"    </a>",
"    ]. Percutaneous tracheostomy has been successfully performed in severely obese patients, but it is recommended that only operators with significant experience attempt this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SPECIFIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all patients are at risk of perioperative complications, the risk is increased in patients who are obese. The major complications of the early postoperative period include hemodynamic instability and respiratory insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Postoperative hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most likely cause of acute hypotension in the early postoperative period is relative hypovolemia from narcotics, anesthetic medications and third spacing. A potential diagnostic problem is that the vasodilatory effects of general anaesthesia can mimic the hemodynamic findings of sepsis, although most modern anesthetics are short-acting and will have little residual hemodynamic effect beyond the immediate postoperative period. Septic shock is less likely unless the patient had an occult infection prior to surgery. Acute hemorrhage, which may be superimposed upon postoperative hypovolemia, is less common, but always a concern in a postoperative patient and must be ruled out rapidly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial management of hypotension should be undertaken with a fluid challenge of between 500 and 1000 mL of crystalloid. At the same time, cardiac enzymes and an electrocardiogram should be obtained to screen for cardiac ischemia and any signs of pulmonary embolism as evidenced by right ventricular strain. The possibility of acute hemorrhage should be assessed by immediate hemoglobin measurement.",
"   </p>",
"   <p>",
"    If the patient's surrogate markers of organ perfusion (blood pressure, urine output, tachycardia) improve with fluid, simple hypovolemia is the most likely etiology of the hypotension. If hypotension does not improve or improves only temporarily, then active bleeding becomes much more likely and the primary surgeon must be contacted immediately. The patient should remain intubated, and be prepared for return to the operating room for reexploration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity can cause other complex and important detrimental effects on the cardiovascular system. The total blood volume and cardiac output are elevated (a hyperdynamic state) in a manner linearly related to excess body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The increase in oxygen delivery is probably driven by the increased oxygen requirements of excess adipose tissue. In normotensive patients with a normal heart rate, this increase in cardiac output is primarily related to an increase in stroke volume, and is accompanied by a decrease in systemic vascular resistance.",
"   </p>",
"   <p>",
"    Over time, this chronic hyperdynamic state can lead to decrease in cardiac performance, decreased left ventricular (LV) contractility, left ventricular hypertrophy, decreased cardiac compliance, and diastolic ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. For these reasons, LV filling pressures are often elevated in obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. As such, the obese critically ill patient can often have difficulties handling the fluid loads that are sometimes required perioperatively, yet they remain dependent on adequate preload. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of gastric aspiration is elevated in obese patients, especially in the postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/73\">",
"     73",
"    </a>",
"    ]. Possible reasons include a large volume of gastric fluid, increased intraabdominal pressure, and an elevated incidence of gastroesophageal reflux disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Placing the patient in reverse Trendelenburg position at 45&ordm; whenever possible may decrease the risk of aspiration and improve pulmonary mechanics. Prophylaxis against the aspiration of low pH gastric contents is warranted, even in the absence of symptoms of gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obese patient appears to be in the moderate-to-high-risk category for venous thromboembolic disease (VTE), and most critically ill bariatric patients are candidates for routine prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. The factors that increase the risk of VTE in this population include decreased mobility, venous stasis, pulmonary hypertension, and possibly a hypercoagulable state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/105\">",
"     105",
"    </a>",
"    ]. Patients should be placed on a combination of sequential compression devices and either low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or unfractionated heparin (5000 units SC three times daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obese patients with a greater-than-average risk of VTE, including those with documented pulmonary hypertension or profoundly limited mobility, may benefit from continuation of their DVT prophylaxis even after discharge from the hospital. Consideration should be given for placement of an inferior vena cava (IVC) filter in patients who either have a contraindication to anticoagulation, or who have pulmonary hypertension and would have difficulty tolerating the hemodynamic insult of even a small pulmonary embolism (PE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multimodality approach to the diagnosis is generally required in hospitalized patients with suspected pulmonary embolism. A contrast-enhanced spiral CT scan has been suggested as a reasonable imaging study for obese patients with suspected pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/109\">",
"     109",
"    </a>",
"    ]. Although spiral CT has excellent sensitivity and specificity, it may be impossible to perform due to weight limitations of some CT scanners. As a result, the weight limits for CT (and MRI) scanners should be verified prior to transporting patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of documented VTE should include full anticoagulation with intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . A weight-based nomogram (using the patients total body weight) can be helpful in obtaining rapid therapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/110\">",
"     110",
"    </a>",
"    ]. Systemic thrombolysis has been achieved in obese patients with documented PE; however, thrombolytic agents should be withheld for at least 10 to 15 days after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Infection and sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome that complicates severe infection and is characterized by systemic inflammation and widespread tissue injury. In this syndrome, tissues remote from the original insult display the cardinal signs of inflammation, including vasodilation, increased microvascular permeability, and leukocyte accumulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The obese patient is at greater-than-average risk for developing sepsis after surgery. Reasons include impaired wound healing related to poorly vascularized adipose tissue, an increased incidence of diabetes and hyperglycemia, and an elevated baseline inflammatory state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Poor wound healing places these patients at increased risk of an anastomotic leak, the primary source of sepsis in the bariatric patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Diagnosis of sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important aspect of managing any patient with a postoperative infection or sepsis is to make the diagnosis. Appropriate management of the bariatric patient with sepsis requires a two-pronged approach with the surgeon looking for and, if necessary, repairing any leak, while the intensivist provides comprehensive nonsurgical management, including aggressive measures to prevent irreversible end-organ dysfunction and death.",
"   </p>",
"   <p>",
"    It is often difficult to diagnose an anastomotic leak in the bariatric patient. Persistent tachycardia and tachypnea are reported to be the most sensitive clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/115\">",
"     115",
"    </a>",
"    ]. The routine placement of drains near the gastrojejunal anastomoses may aid the surgeon in the early recognition of a leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/116\">",
"     116",
"    </a>",
"    ]. Although Gastrografin swallowing studies are important in the work-up of a potential leak, when the clinical condition of the bariatric patient continues to deteriorate, surgical reevaluation is warranted, even in the setting of a negative swallowing study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Management of sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to properly manage the septic bariatric patient, multiple issues need to be addressed in a rapid and simultaneous fashion. These include surgical source control, appropriate cultures of blood, urine and sputum, and the administration of broad-spectrum intravenous empiric antibiotic therapy (at least two agents, covering a combination of gram-positive, gram-negative and anaerobic organisms). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although several landmark studies of sepsis management did not focus on the obese critically ill patient, only two of these studies had specific weight exclusion criteria (",
"    <a class=\"graphic graphic_table graphicRef62547 \" href=\"mobipreview.htm?27/55/28539\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/44,81,119-122\">",
"     44,81,119-122",
"    </a>",
"    ]. We try to incorporate these findings into the management of critically ill obese patients to the greatest degree possible. Specific examples include the use of low tidal volume ventilation for acute respiratory distress syndrome as mentioned above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/44,81\">",
"     44,81",
"    </a>",
"    ] and the modalities described in the following paragraphs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamic support of the septic patient involves aggressive volume repletion, usually with one liter boluses of 0.9 percent saline until a central venous pressure (CVP) of 6 to 12 mmHg is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/114\">",
"     114",
"    </a>",
"    ]. Despite the widespread use of the pulmonary artery (PA) catheter, there have been multiple randomized trials documenting the lack of benefit of its routine use in the critically ill patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the use of an",
"    <strong>",
"     early",
"    </strong>",
"    goal-directed resuscitation approach without the use of a PA catheter has been associated with a significant improvement in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/121\">",
"     121",
"    </a>",
"    ]. Vasopressors (primarily norepinephrine) should be started if the patient remains hypotensive after adequate volume resuscitation, with a goal mean arterial pressure (MAP) of 60 to 65 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/114\">",
"     114",
"    </a>",
"    ]. The urine output should be maintained at &ge;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per h [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily renal replacement therapy can be considered if renal failure ensues, although no trials have proven the benefit of continuous compared to intermittent renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis was observed in 5 of 353 patients (1.4 percent) following laparoscopic duodenal switch procedures performed at a single center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/123\">",
"     123",
"    </a>",
"    ]. Most patients reported muscle pain, and mean creatinine kinase elevations of nearly 20,000 were noted. The proposed mechanisms of injury include critical hypoperfusion of poorly vascularized dependent regions of muscle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop postoperative complications and require prolonged intensive care are at risk of hypercalcemia, probably because of immobility following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/2/32810/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severely obese patients have a greater-than-average risk of developing serious complications requiring intensive care and monitoring in the postoperative period. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a properly sized blood pressure cuff is essential for accurate hemodynamic monitoring in obese patients. If too small a cuff is used, the pressure generated by inflating the cuff may not be fully transmitted to the brachial artery, which can lead to overestimation of the systolic pressure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An arterial line allows both continuous blood pressure monitoring and access to blood for analysis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripherally inserted central catheters (PICC) are useful for reliable vascular access in obese postoperative patients. The femoral location should be avoided if at all possible. The use of ultrasound to assist in the placement of central venous catheters is recommended. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The critical care pharmacist should be consulted for advice regarding appropriate medication dosing. Obese patients have a larger volume of distribution for lipophilic drugs, but a decrease in lean body mass and tissue water, compared to nonobese controls. These changes predispose obese patients to both subtherapeutic and toxic responses to medication. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Weight based dosing of medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolic energy requirements of critically ill patients are generally estimated based on actual body weight using the Harris-Benedict equation. However, this equation may overestimate the metabolic demand of critically ill obese patients, and can lead to overfeeding. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severely obese patients are at risk of perioperative respiratory dysfunction due to underlying comorbid conditions, particularly obesity hypoventilation syndrome (OHS) and obstructive sleep apnea (OSA). OSA and OHS can complicate management of severely obese patients because of an abnormally small upper airway and chronic hypercarbic respiratory failure, respectively. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Obesity hypoventilation syndrome and obstructive sleep apnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Static pulmonary compliance is decreased in the severely obese patient due to a heavy, noncompliant chest wall, rather than pulmonary parenchymal restriction. Aggressive perioperative pulmonary toilet, as well as having the patient in the sitting position as much as possible, decreases the incidence of aspiration as well as time to liberation from mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mechanical ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the postoperative bariatric patient demonstrates either respiratory or hemodynamic instability in the immediate postoperative period, the patient should remain intubated and brought to an intensive care unit as soon as possible. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Extubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early tracheostomy should be performed for critically ill bariatric patients if it appears that they will require prolonged mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Role of tracheostomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/1\">",
"      Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/2\">",
"      Colquitt J, Clegg A, Sidhu M, Royle P. Surgery for morbid obesity. Cochrane Database Syst Rev 2003; :CD003641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/3\">",
"      NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/4\">",
"      Fisher BL, Schauer P. Medical and surgical options in the treatment of severe obesity. Am J Surg 2002; 184:9S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/5\">",
"      Doherty C. Vertical banded gastroplasty. Surg Clin North Am 2001; 81:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/6\">",
"      Vella M, Galloway DJ. Laparoscopic adjustable gastric banding for severe obesity. Obes Surg 2003; 13:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/7\">",
"      Fox SR, Fox KM, Srikanth MS, Rumbaut R. The Lap-Band system in a North American population. Obes Surg 2003; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/8\">",
"      El-Solh AA. Clinical approach to the critically ill, morbidly obese patient. Am J Respir Crit Care Med 2004; 169:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/9\">",
"      Brolin RE. Gastric bypass. Surg Clin North Am 2001; 81:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/10\">",
"      Gonzalez R, Bowers SP, Venkatesh KR, et al. Preoperative factors predictive of complicated postoperative management after Roux-en-Y gastric bypass for morbid obesity. Surg Endosc 2003; 17:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/11\">",
"      El-Solh A, Sikka P, Bozkanat E, et al. Morbid obesity in the medical ICU. Chest 2001; 120:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/12\">",
"      Livingston EH. Procedure incidence and in-hospital complication rates of bariatric surgery in the United States. Am J Surg 2004; 188:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/13\">",
"      El Shobary H, Backman S, Christou N, Schricker T. Use of critical care resources after laparoscopic gastric bypass: effect on respiratory complications. Surg Obes Relat Dis 2008; 4:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/14\">",
"      Bull&oacute; M, Garc&iacute;a-Lorda P, Megias I, Salas-Salvad&oacute; J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/15\">",
"      Levi D, Goodman ER, Patel M, Savransky Y. Critical care of the obese and bariatric surgical patient. Crit Care Clin 2003; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/16\">",
"      Wilson JA, Clark JJ. Obesity: impediment to wound healing. Crit Care Nurs Q 2003; 26:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/17\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/18\">",
"      Arcila D, Vel&aacute;zquez D, Gamino R, et al. Quality of life in bariatric surgery. Obes Surg 2002; 12:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/19\">",
"      Bocchieri LE, Meana M, Fisher BL. A review of psychosocial outcomes of surgery for morbid obesity. J Psychosom Res 2002; 52:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/20\">",
"      Yaegashi M, Jean R, Zuriqat M, et al. Outcome of morbid obesity in the intensive care unit. J Intensive Care Med 2005; 20:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/21\">",
"      Goulenok C, Monchi M, Chiche JD, et al. Influence of overweight on ICU mortality: a prospective study. Chest 2004; 125:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/22\">",
"      Bercault N, Boulain T, Kuteifan K, et al. Obesity-related excess mortality rate in an adult intensive care unit: A risk-adjusted matched cohort study. Crit Care Med 2004; 32:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/23\">",
"      Abir F, Bell R. Assessment and management of the obese patient. Crit Care Med 2004; 32:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/24\">",
"      Turnock C, Kelleher M. Maintaining patient dignity in intensive care settings. Intensive Crit Care Nurs 2001; 17:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/25\">",
"      Gallagher SM. Morbid obesity: a chronic disease with an impact on wounds and related problems. Ostomy Wound Manage 1997; 43:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/26\">",
"      Flanagan SA. Obesity: The Last Bastion of Prejudice. Obes Surg 1996; 6:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/27\">",
"      Murray D. Morbid obesity--psychosocial aspects and surgical interventions. AORN J 2003; 78:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/28\">",
"      Troia C. Promoting positive outcomes in obese patients. Plast Surg Nurs 2002; 22:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/29\">",
"      Davidson JE, Callery C. Making the most of your time: the benefits of converting patient education programs into continuing nursing education. Obes Surg 2000; 10:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/30\">",
"      Mathison CJ. Skin and wound care challenges in the hospitalized morbidly obese patient. J Wound Ostomy Continence Nurs 2003; 30:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/31\">",
"      Barr J, Cunneen J. Understanding the bariatric client and providing a safe hospital environment. Clin Nurse Spec 2001; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/32\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. BMJ 2001; 322:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/33\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension: Blood pressure measurement. Part II-conventional sphygmomanometry: technique of auscultatory blood pressure measurement. BMJ 2001; 322:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/34\">",
"      Miller AH, Roth BA, Mills TJ, et al. Ultrasound guidance versus the landmark technique for the placement of central venous catheters in the emergency department. Acad Emerg Med 2002; 9:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/35\">",
"      Gann M Jr, Sardi A. Improved results using ultrasound guidance for central venous access. Am Surg 2003; 69:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/36\">",
"      Black IH, Blosser SA, Murray WB. Central venous pressure measurements: peripherally inserted catheters versus centrally inserted catheters. Crit Care Med 2000; 28:3833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/37\">",
"      Griffiths VR, Philpot P. Peripherally inserted central catheters (PICCs): do they have a role in the care of the critically ill patient? Intensive Crit Care Nurs 2002; 18:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/38\">",
"      Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134:172.",
"     </a>",
"    </li>",
"    <li>",
"     O'Grady, NP, Alexander, M, Dellinger, EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1. www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm (Accessed on June 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/40\">",
"      Varon J, Marik P. Management of the obese critically ill patient. Crit Care Clin 2001; 17:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/41\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/42\">",
"      Elamin EM. Nutritional care of the obese intensive care unit patient. Curr Opin Crit Care 2005; 11:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/43\">",
"      Cutts ME, Dowdy RP, Ellersieck MR, Edes TE. Predicting energy needs in ventilator-dependent critically ill patients: effect of adjusting weight for edema or adiposity. Am J Clin Nutr 1997; 66:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/44\">",
"      van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/45\">",
"      NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/46\">",
"      Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/47\">",
"      Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/48\">",
"      Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/49\">",
"      Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012; 32:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/50\">",
"      Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/51\">",
"      Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/52\">",
"      Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/53\">",
"      Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol 1985; 42:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/54\">",
"      Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/55\">",
"      Pories WJ, van Rij AM, Burlingham BT, et al. Prophylactic cefazolin in gastric bypass surgery. Surgery 1981; 90:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/56\">",
"      Hall RG 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008; 121:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/57\">",
"      Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/58\">",
"      Myzienski AE, Lutz MF, Smythe MA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy 2010; 30:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/59\">",
"      Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician 1996; 54:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/60\">",
"      Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/61\">",
"      Bauer SR, Ou NN, Dreesman BJ, et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clin Proc 2009; 84:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/62\">",
"      Al-Yaseen E, Wells PS, Anderson J, et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/63\">",
"      Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87:817.",
"     </a>",
"    </li>",
"    <li>",
"     Correction to Endorsements in: Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines chestjournal.chestpubs.org (Accessed on May 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/65\">",
"      Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/66\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/67\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/68\">",
"      Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/69\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/70\">",
"      Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/71\">",
"      Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/72\">",
"      den Herder C, Schmeck J, Appelboom DJ, de Vries N. Risks of general anaesthesia in people with obstructive sleep apnoea. BMJ 2004; 329:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/73\">",
"      Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/74\">",
"      Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg 2003; 13:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/75\">",
"      Williamson JA, Webb RK, Szekely S, et al. The Australian Incident Monitoring Study. Difficult intubation: an analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/76\">",
"      Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. Anesth Analg 2002; 94:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/77\">",
"      Juvin P, Lavaut E, Dupont H, et al. Difficult tracheal intubation is more common in obese than in lean patients. Anesth Analg 2003; 97:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/78\">",
"      Ladosky W, Botelho MA, Albuquerque JP Jr. Chest mechanics in morbidly obese non-hypoventilated patients. Respir Med 2001; 95:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/79\">",
"      Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci 1999; 318:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/80\">",
"      Levitan R, Ochroch EA. Airway management and direct laryngoscopy. A review and update. Crit Care Clin 2000; 16:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/81\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/82\">",
"      Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest 2001; 120:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/83\">",
"      Pelosi P, Ravagnan I, Giurati G, et al. Positive end-expiratory pressure improves respiratory function in obese but not in normal subjects during anesthesia and paralysis. Anesthesiology 1999; 91:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/84\">",
"      Kress JP, Gehlbach B, Lacy M, et al. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003; 168:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/85\">",
"      Gehlbach BK, Kress JP. Sedation in the intensive care unit. Curr Opin Crit Care 2002; 8:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/86\">",
"      Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/87\">",
"      Vaughan RW, Bauer S, Wise L. Effect of position (semirecumbent versus supine) on postoperative oxygenation in markedly obese subjects. Anesth Analg 1976; 55:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/88\">",
"      Davidson JE, Callery C. Care of the obesity surgery patient requiring immediate-level care or intensive care. Obes Surg 2001; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/89\">",
"      Masa JF, Celli BR, Riesco JA, et al. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest 2001; 119:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/90\">",
"      Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/91\">",
"      Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/92\">",
"      Hida W, Okabe S, Tatsumi K, et al. Nasal continuous positive airway pressure improves quality of life in obesity hypoventilation syndrome. Sleep Breath 2003; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/93\">",
"      Watters M, Waterhouse P. Percutaneous tracheostomy in morbidly obese patients. Anaesthesia 2002; 57:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/94\">",
"      Mansharamani NG, Koziel H, Garland R, et al. Safety of bedside percutaneous dilatational tracheostomy in obese patients in the ICU. Chest 2000; 117:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/95\">",
"      Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis 1985; 27:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/96\">",
"      ALEXANDER JK, DENNIS EW, SMITH WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/97\">",
"      Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993; 306:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/98\">",
"      Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/99\">",
"      de Divitiis O, Fazio S, Petitto M, et al. Obesity and cardiac function. Circulation 1981; 64:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/100\">",
"      Alaud-din A, Meterissian S, Lisbona R, et al. Assessment of cardiac function in patients who were morbidly obese. Surgery 1990; 108:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/101\">",
"      Vaughan RW, Bauer S, Wise L. Volume and pH of gastric juice in obese patients. Anesthesiology 1975; 43:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/102\">",
"      Harter RL, Kelly WB, Kramer MG, et al. A comparison of the volume and pH of gastric contents of obese and lean surgical patients. Anesth Analg 1998; 86:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/103\">",
"      Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114:531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/104\">",
"      Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/105\">",
"      Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 2003; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/106\">",
"      Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 2000; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/107\">",
"      Ferrell A, Byrne TK, Robison JG. Placement of inferior vena cava filters in bariatric surgical patients--possible indications and technical considerations. Obes Surg 2004; 14:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/108\">",
"      Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/109\">",
"      Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/110\">",
"      Linke LC, Katthagen BD. Weight-based heparin dosing is more effective in the treatment of postoperative deep vein thrombosis. Arch Orthop Trauma Surg 1999; 119:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/111\">",
"      Pulipati RC, Lazzaro RS, Macura J, Savel RH. Successful thrombolysis of submassive pulmonary embolism after bariatric surgery: expanding the indications and addressing the controversies. Obes Surg 2003; 13:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/112\">",
"      Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/113\">",
"      Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/114\">",
"      Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003; 31:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/115\">",
"      Hamilton EC, Sims TL, Hamilton TT, et al. Clinical predictors of leak after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Surg Endosc 2003; 17:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/116\">",
"      Serafini F, Anderson W, Ghassemi P, et al. The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. Obes Surg 2002; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/117\">",
"      Sims TL, Mullican MA, Hamilton EC, et al. Routine upper gastrointestinal Gastrografin swallow after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/118\">",
"      Ganci-Cerrud G, Herrera MF. Role of radiologic contrast studies in the early postoperative period after bariatric surgery. Obes Surg 1999; 9:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/119\">",
"      Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/120\">",
"      Richard C, Warszawski J, Anguel N, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/121\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/122\">",
"      Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/123\">",
"      Khurana RN, Baudendistel TE, Morgan EF, et al. Postoperative rhabdomyolysis following laparoscopic gastric bypass in the morbidly obese. Arch Surg 2004; 139:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/2/32810/abstract/124\">",
"      Alborzi F, Leibowitz AB. Immobilization hypercalcemia in critical illness following bariatric surgery. Obes Surg 2002; 12:871.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 584 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32810=[""].join("\n");
var outline_f32_2_32810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obesity bias and care with dignity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nursing care and equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WEIGHT BASED DOSING OF MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calculator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-infectives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sedatives and analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuromuscular blocking agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PULMONARY CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Obesity hypoventilation syndrome and obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intubation and anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Extubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Role of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SPECIFIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Postoperative hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Infection and sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Diagnosis of sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Management of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/584|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/37/15965\" title=\"figure 1\">",
"      Annual bariatric procedures US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/584|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/6/8302\" title=\"table 1\">",
"      LMWH doses in obese patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/55/28539\" title=\"table 2\">",
"      Obesity and ICU trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=related_link\" title=\"calculator 1\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21991?source=related_link\">",
"      Assessment of respiratory distress in the mechanically ventilated patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38519?source=related_link\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/30/8679?source=related_link\">",
"      Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=related_link\">",
"      Phenytoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_2_32811="Findings in RP fibrosis";
var content_f32_2_32811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Associated diagnoses among 491 patients with retroperitoneal fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td class=\"centered\">",
"        67.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methysergide exposure",
"       </td>",
"       <td class=\"centered\">",
"        12.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All malignancies",
"       </td>",
"       <td class=\"centered\">",
"        7.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinal fibrosis",
"       </td>",
"       <td class=\"centered\">",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periaortic inflammation-arteritis",
"       </td>",
"       <td class=\"centered\">",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric fibrosis",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sclerosing cholangitis",
"       </td>",
"       <td class=\"centered\">",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal aortic aneurysm",
"       </td>",
"       <td class=\"centered\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"       <td class=\"centered\">",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombophlebitis",
"       </td>",
"       <td class=\"centered\">",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reidel's thyroiditis",
"       </td>",
"       <td class=\"centered\">",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td class=\"centered\">",
"        5.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Koep L, Zuidemia GD. Surgery 1977; 81:250.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32811=[""].join("\n");
var outline_f32_2_32811=null;
var title_f32_2_32812="DDx ALK positive ALCL";
var content_f32_2_32812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of ALK positive anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features/other",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        ALK positive anaplastic large cell lymphoma",
"       </td>",
"       <td>",
"        Large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm (\"hallmark cells\"). High proliferative fraction. Often shows a cohesive growth pattern often preferentially in the lymph node sinuses or paracortex.",
"       </td>",
"       <td>",
"        Homogeneous and strong expression of CD30 in a membrane and Golgi pattern. Usually express one or more T cell antigens (ie, CD2, CD3, CD5, CD7). Do not express B cell antigens. CD 15 and PAX5/BSAP are negative.",
"       </td>",
"       <td>",
"        ALK positivity can be detected by immunostains or molecular genetics and is universally present. The majority demonstrate rearranged TCR genes.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        ALK negative anaplastic large cell lymphoma",
"       </td>",
"       <td>",
"        Disease involves the lymph nodes and/or extracutaneous extranodal tissues. Histology resembles ALK positive ALCL.",
"       </td>",
"       <td>",
"        Immunophenotype similar to ALK positive ALCL",
"       </td>",
"       <td>",
"        ALK negative. TCR genes rearranged.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Primary cutaneous anaplastic large cell lymphoma",
"       </td>",
"       <td>",
"        Disease is confined to the skin. Histology resembles ALK positive ALCL.",
"       </td>",
"       <td>",
"        Immunophenotype similar to ALK positive ALCL",
"       </td>",
"       <td>",
"        ALK negative. TCR genes rearranged.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Diffuse large B cell lymphoma",
"       </td>",
"       <td>",
"        Large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction. May morphologically resemble ALCL.",
"       </td>",
"       <td>",
"        Express pan B cell antigens (CD19, CD20, CD22, CD79a). Small subset of tumors with ALK gene rearrangements may be positive for ALK by immunostaining.",
"       </td>",
"       <td>",
"        The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. Rare tumors have ALK gene rearrangements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin lymphoma",
"       </td>",
"       <td>",
"        The reticular variant of lymphocyte depleted Hodgkin lymphoma may be difficult to distinguish morphologically from ALCL. The HL tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background.",
"       </td>",
"       <td>",
"        The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45. PAX5/BSAP are expressed. T cell antigens are generally negative (rare exceptions). ALK negative.",
"       </td>",
"       <td>",
"        There is no single cytogenetic change that is typical or diagnostic. Carry IgH gene rearrangements. ALK negative.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALK: anaplastic lymphoma kinase gene; ALCL: anaplastic large cell lymphoma; TCR: T cell receptor; HL: Hodgkin lymphoma.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32812=[""].join("\n");
var outline_f32_2_32812=null;
var title_f32_2_32813="Body cast prevents lung injury";
var content_f32_2_32813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Body cast protects against positive pressure ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of limited intrathoracic expansion by means of a body cast on ventilator-induced lung injury in rabbits. Rabbits were ventilated with 15, 30, and 45 cmH20 peak inspiratory pressure for one hour. Lung injury was assessed by changes in the capillary filtration coefficient (Kfc). The closed chest group had increasing lung injury at 30 and 45 cmH20 peak inspiratory pressures; this complication was completely prevented by the presence of a body cast, indicating that the injury is due to the high tidal volumes induced at these airway pressures (\"volutrauma\") and not the high airway pressure itself.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hernandez, LA, Peevy, KJ, Moise, AA, Parker, JC, J Appl Physiol 1989; 66:2364.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32813=[""].join("\n");
var outline_f32_2_32813=null;
var title_f32_2_32814="Esophageal perforation UGI";
var content_f32_2_32814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal perforation in Boerhaave's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Water-soluble contrast esophagram shows a distal esophageal perforation (arrow) with extravasation of contrast material into the mediastinum and left pleural space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32814=[""].join("\n");
var outline_f32_2_32814=null;
var title_f32_2_32815="AV reentrant tachycardia";
var content_f32_2_32815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    AV reentrant tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 106px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AV reentrant tachycardia breaking to sinus rhythm with Wolff-Parkinson-White syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_2_32815=[""].join("\n");
var outline_f32_2_32815=null;
